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ABSTRACT 
 
Introduction: Mozambique is one of the countries most affected by the AIDS epidemic in the 
world, with an HIV prevalence of 11.5% in the 15-49 year age group. HIV is associated with a 
higher prevalence of both Hepatitis B (HBV) and Hepatitis C (HCV). In sub-Saharan Africa, co-
infection with HIV and HBV and syphilis is highly prevalent and these infections can be 
transmitted from mother to child and may cause severe morbidity in their offspring. Contributing 
factors to the current high rates of HIV and HBV include abuse and violence, gender 
inequalities, unequal access to education and lack of economic opportunities. Intimate partner 
violence (IPV) is a major public health problem worldwide but research on IPV in Africa, 
including Mozambique, remains limited. The prevalence of sexual and physical intimate 
partner violence against women is high in the majority of sub-Saharan African countries.  
 
Methods: The research was cross-sectional, carried out in six health units in Nampula 
Province, Mozambique, from February 2013 to January 2014. One in every three pregnant 
women who visited primary health facilities for the first prenatal appointment was eligible and 
invited to participate. In total, 1440 pregnant women were invited to participate and 1216 
(84.4%) agreed to participate. A similar sampling procedure was performed for all HIV and 
AIDS patients attending antiretroviral clinics. A total of 761 were invited to participate and 742 
(97.5%) agreed to participate. After considerable losses during transport, 666 (54.8%) and 279 
(40.3%) plasma samples were available for laboratory analysis, from pregnant women and HIV 
positive patients, respectively. Interviews were conducted using structured questionnaires on 
demographic variables, IPV and knowledge, and attitudes regarding selected infectious 
diseases. Only 869 pregnant women were able to answer the Conflict Tactics Scale 2 (CTS2) 
for IPV. The Chi-square test was used to compare proportions, with significance tested using 
a p-value of < 0.05. Odds ratios (OR) and respective 95% confidence intervals (95%CI) were 
calculated. Logistic regression was used to estimate the association of sexual and physical 
abuse with covariates, adjusting for the potential confounders. The data analysis was 
performed using the statistical software SPSS, version 22. To evaluate the knowledge and 
attitudes among pregnant women, Latent Class Models (LCM) was used to identify specific 
groups in terms of knowledge about HIV, HBV and HCV modes of transmission. Thus, class 1 
was represented by women with a high proportion of correct answers, therefore, high 
knowledge; class 2 was represented by women who gave almost half of the correct responses 
without misconceptions and class 3 was represented by women who gave a lower proportion 
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of correct answers and misconceptions. Solutions with 1, 2 and 3 classes were tested from 
which we chose the one that showed the smallest Bayesian Information Criterion (BIC). The 
comparisons of proportions by latent classes were performed using the Chi-square test or 
Fisher’s exact test, with a p-value of < 0.05, between groups.  
The prevalence of HIV infection was 30.3%, 40 women (6.2%) had chronic Hepatitis B and 
451 (69.9%) had had a previous Hepatitis B infection, 4 (0.9%) had Hepatitis C and 3 (0.5%) 
had Syphilis. Among the 201 HIV-positive women, 29 (14.4%) were aware of their infection 
and 17 (58.6%) were under treatment. There were no differences between the two groups 
regarding condom use in the last sexual intercourse. 
The prevalences of HIV, HBV, HCV and syphilis co-infection were measured on sera samples, 
which suffered considerable losses during transport. For the study were used 638 and 277 
sera samples available to perform laboratory analysis, from pregnant women and HIV positive 
patients, respectively. Serology for HIV, hepatitis B (HBsAg, HBeAg, anti-HBc), hepatitis C 
(anti-HCV) and syphilis was performed using standard laboratory procedures and algorithms. 
Statistical analyses were performed using SPSS software for Windows, version 22.0 using a 
p-value of <0.05 for significance. 
 
Results: Sexual abuse and physical violence occurred in every age group. The prevalence of 
lifetime sexual abuse was 49% and of physical abuse was 46%. During the past year, the 
prevalence was 46% and 44% for sexual and physical abuse, respectively. Significant 
associations were found between previous neonatal deaths and being physically abused, 
during the lifetime (OR= 3.00, 95% IC: 1.67 to 5:39), and the past year (OR=3.23, 95% CI: 
1.80 to 5.80) 
The distribution of women in each class for knowledge regarding HIV was 687 (60.5%), 295 
(26.0%) and 154 (13.6%), in class 1, 2 and 3, respectively. For HBV knowledge, the distribution 
was 274 (23.6%), 149 (12.8%) and 738 (63.6%) for class 1, 2 and 3, respectively. For HCV, 
the knowledge distribution was: class 1, 214 (18.4%); class 2, 146 (12.6%) and class 3, 801 
(69.0%). 
Among pregnant women, the prevalence of HIV infection was 30.3%, 40 women (6.2%) had 
chronic Hepatitis B and 451 (69.9%) had had a previous Hepatitis B, 4 (0.9%) had Hepatitis C 
and 3 (0.5%) had Syphilis infection. Among the 201 HIV- positive women, 29 (14.4%) were 
aware of their infection and 17 (58.6%) were under treatment. The prevalence of HIV/HBsAg+, 
HIV/anti-HCV and HIV/syphilis co-infection, were 3.6%, 0.2% and 0.5%, respectively. There 
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were no differences between women who were previously aware of their HIV positive status 
and those who were not aware, regarding condom use in the last sexual intercourse (P >0.5).  
 
Conclusion: The prevalence of intimate partner violence is very high among women in this 
study. Contact with women in prenatal care provides a window of opportunity for identifying 
women who experience violence and screening for sexually transmitted infections. Latent class 
models (LCM) showed a high knowledge of HIV modes of transmission, but that of HBV and 
HCV was little known. In this setting, HBV may also have been transmitted horizontally in 
children, and screening for HBsAg among pregnant women could contribute substantially to 
avert the negative impact on morbidity and mortality especially for HIV/HBV coinfected 
individuals. 
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Resumo: 
Introdução: Moçambique é um dos países mais afetados pela epidemia do SIDA, no mundo, 
com uma prevalência de VIH de 11,5% no grupo etário dos 15-49 anos. O VIH está associado 
a uma maior prevalência de Hepatite B (VHB) e Hepatite C (VHC). Na África Subsaariana, a 
coinfecção por VIH e VHB e sífilis é altamente prevalente e estas infeções podem ser 
transmitidas de mãe para o filho e pode causar morbidade grave em sua prole. Fatores que 
contribuem para as atuais altas taxas de VIH e VHB incluem abuso e violência, as 
desigualdades de género, acesso desigual à educação e à falta de oportunidades 
económicas. Violência por Parceiro Íntimo (IPV) é um importante problema de saúde pública 
em todo o mundo, mas as pesquisas sobre IPV em África, incluindo Moçambique continua a 
ser limitado. A prevalência de violência por parceiro íntimo sexual e física contra as mulheres, 
na maioria dos países da África Subsaariana é alta. 
 
Métodos: A pesquisa foi transversal, realizado em seis unidades de saúde na província de 
Nampula, Moçambique, a partir de fevereiro de 2013 a janeiro de 2014. Uma em cada três 
mulheres grávidas que foram as consultas pré-natais, no Centro de Saúde, para a primeira 
consulta pré-natal era elegível e convidados a participar. No total, 1440 mulheres grávidas 
foram convidados a participar e 1.216 (84,4%) concordaram em participar da entrevista, Um 
procedimento de amostragem similar foi realizado para as pessoas portadoras do VIH e de 
SIDA que frequentaram as consultas de tratamento de tratamento antirretroviral. Assim, um 
total de 761 portadores de VIH e doentes de SIDA foram convidados a participar e, 742 
(97,5%) concordaram em participar. Após perdas consideráveis durante o transporte, 666 
(54.8%) e 279 (40.3%) amostras de plasma estavam disponíveis para análise laboratorial, de 
mulheres grávidas e pacientes VIH positivos, respetivamente. As entrevistas foram realizadas 
por meio de questionários estruturados. Apenas 869 mulheres grávidas foram capazes de 
responder a Conflito Tactics Scale 2 (CTS2), e o teste do qui-quadrado foi usado para 
comparar proporções. Significância das associações de foram testadas usando um valor de p 
<0,05. Odds ratio (OR) e os respetivos intervalos de confiança de 95% (IC95%) foram 
calculados. A regressão logística foi usada para estimar a associação do abuso sexual e físico 
com covariáveis, ajustado para os potenciais fatores de confundimento. A análise dos dados 
foi realizada utilizando o software estatístico SPSS, versão 22. Para avaliar o conhecimento e 
atitude das mulheres grávidas, foi usado o Latentes Classe Models (LCM) para identificar 
grupos específicos em termos de conhecimento sobre o VIH, VHB e VHC modos de 
transmissão. Assim, a classe 1 foi representada por mulheres com uma elevada percentagem 
de respostas corretas, portanto, elevado conhecimento; classe 2 foi representada por 
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mulheres que deram quase metade das respostas corretas, sem equívocos e classe 3, foi 
representada por mulheres que deram uma menor proporção de respostas certas e com 
equívocos. Soluções com 1, 2 e 3 classes foram testadas a partir das quais escolhemos o que 
apresentou o menor Critério de Informação Bayesiana (BIC). As comparações de proporções 
por classes latentes foram realizadas utilizando o teste do qui-quadrado ou teste exato de 
Fisher, nível de significância foi testada usando o valor de p <0,05, entre os grupos. 
As prevalências das infeções por VIH, VHB e VHC e sífilis e, coinfecções foram medidas 
através de amostras de plasma, que parte delas foram perdidas durante o transporte. Para o 
estudo foram feitos testes laboratoriais de 638 e 277 amostras de plasma de mulheres 
grávidas e pacientes VIH positivos, respetivamente. As serologias para o VIH, hepatite B 
(HBsAg, HBeAg, anti-HBc), hepatite C (anti-VHC) e sífilis foram realizadas utilizando 
procedimentos padronizados de laboratório e algoritmos. As análises estatísticas foram 
realizadas utilizando software SPSS para Windows, versão 22.0 usando um valor de p <0,05 
para significância estatística. 
 
Resultados: O abuso sexual e a violência física ocorreram em todas as faixas etárias. A 
prevalência de abuso sexual durante a vida foi de 49% e de abuso físico foi de 46%. Durante 
o ano passado, a prevalência foi de 46% e 44% para o abuso sexual e físico, respetivamente. 
Foram encontradas associações significativas entre os óbitos neonatais anteriores e tendo 
sido abusadas fisicamente, durante ao longo da vida da mulher (OR = 3,00, 95% IC: 1,67 a 
5:39), e no ano passado (OR = 3,23, 95% CI: 1,80-5,80). 
A distribuição das mulheres em cada uma das classes do conhecimento sobre VIH foi 687 
(60,5%), 295 (26,0%) e 154 (13,6%), pertencentes à classe 1, 2 e 3, respetivamente. Para o 
conhecimento do HBV, a distribuição foi de 274 (23,6%), 149 (12,8%) e 738 (63,6%) para as 
classes 1, 2 e 3, respetivamente. Para o HCV, o conhecimento foi distribuído nas seguintes 
classes 1, 214 (18,4%); classe 2, 146 (12,6%) e classe 3, 801 (69,0%). 
Entre as mulheres grávidas, a prevalência da infeção pelo VIH foi de 30,3%, 40 mulheres 
(6,2%) tinham hepatite B crónica e 451 (69,9%) tiveram infeção pela Hepatite B, 4 (0,9%) 
tiveram hepatite C e 3 (0,5%) infeção pela sífilis. Entre as 201 mulheres VIH-positivas, 29 
(14,4%) estavam cientes da sua infeção e 17 (58,6%) estavam em tratamento. A coinfecção 
por VIH/HBsAg +, VIH/anti-VHC e VIH/sífilis, foi de 3,6%, 0,2% e 0,5%, respetivamente. O uso 
do preservativo na última relação sexual, o estudo não encontrou nenhuma diferença entre o 
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grupo de mulheres que sabia previamente o seu estado serológico positivo em relação ao 
VIH, do das que não sabia o seu estado serológico antes da consulta (P >0.5). 
 
Conclusão: A prevalência de violência da mulher pelo parceiro íntimo é muito alta entre as 
mulheres, neste estudo e, as consultas pré-natais podem ser uma janela de oportunidade para 
identificar as mulheres que sofreram violência e rastreio de infeções sexualmente 
transmissíveis. O Modelo Latente de Classes (LCM) mostrou um alto conhecimento sobre os 
modos da transmissão do VIH, seguido pelo VHB e por fim o VHC. O estudo também revelou 
que, deve ser considerada a transmissão do vertical do VHB e, o rastreio do HBsAg em 
mulheres grávidas pode contribuir substancialmente para reduzir o impacto negativo destas 
doenças na morbilidade e mortalidade em particular de indivíduos coinfetados pelo VIH/VHB, 
bem como da transmissão vertical do VHB.  
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1. INTRODUCTION 
 
The Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome 
(AIDS) epidemic continues to be a cause for concern worldwide. In 2014, estimates showed 
that 36.9 million people were living with HIV and AIDS. Only in 2014, about 2 million new 
people were infected with HIV and the number of deaths related to AIDS illness 1.2 million 
people worldwide (1). In sub-Saharan Africa, there are 24 million people living with HIV (2). 
Since 2000, about 38.1 million people have become infected by HIV and 25.3 million people 
have died of AIDS (1). In 2012 there were an estimated 35.3 million people living with HIV and 
AIDS worldwide, and globally there were 2.3 million new infections, showing a 33% decline in 
the number of new infections from 3.4 million in 2001 (3). Sub-Saharan Africa continues to be 
the part of the world hardest hit by the HIV pandemic (4). Mozambique is one of the countries 
most affected by the epidemic, with an HIV  prevalence of 11.5% in the 15-49 year age group 
(5, 6). 
Globally, estimates show that of all people living with HIV worldwide, about 2 million - 
4 million also have Hepatitis B Virus (HBV) infection and 4 million – 5 million people Hepatitis 
C virus (HCV) infection (2). HIV is associated with a higher prevalence of both HBV and HCV 
in sub-Saharan Africa, a systematic review and meta-analysis of people infected with HIV 
showed Hepatitis B surface Antigen (HBsAg) and antibodies to Hepatitis C Virus (anti-HCV) 
prevalence of 15% and 7%, respectively. The risk ratios (RRs) for being HBsAg positive and 
anti-HCV positive were 1,40 (95% Confidence Interval (CI) 1.16-1.69) and 1.60 (95% CI 1.05-
2.45) in HIV-infected, as compared to HIV-uninfected, patients (7). Hepatitis B virus, HIV-1, 
and Treponema pallidum represent major public health problems in sub-Saharan Africa. These 
infections can be transmitted from mother to child and may cause severe morbidity in their 
offspring. Co-infection with HIV-1 and HBV and syphilis is highly prevalent and far from 
negligible among antenatal care attendees and Individuals Attending Centres for screening 
sexually transmitted infections (8, 9). Shared transmission paths mean that co-infection with 
HIV, HBV, HCV, and syphilis constitute a joint public health problem (10-12). 
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An estimated 350 million people are chronically infected with HBV and are at risk of 
developing hepatocellular carcinoma (HCC), with over 2 billion individuals being exposed to 
the virus (13). Chronic infection with HBV is the most frequent cause of this type of a tumor, 
representing more than 50% of global cases. In HCC endemic regions, this number rises to 
almost 70 - 80% of the cases, becoming the sixth most common type of cancer today. The 
incidence of HCC among individuals with chronic HBV infection ranges from 400 to 800 in 
males and from 120 to 180 in females, per 100.000 persons/year. It occupies third place in 
annual cancer mortality rates. Approximately 80% of HCCs cases occur in developing 
countries in regions such as the Asia-Pacific and Sub-Saharan Africa where HBV infection is 
endemic and has a high incidence (14, 15). 
 
In Africa, about 50 million people are a chronic carrier of HBV, with 25% of mortality 
risk. The sub-Saharan Africa countries are in a high endemicity region with HBsAg carrier rates 
between 9 – 20% (16). 
 
HBV infection is acquired during the prenatal period, at birth or during the first months 
or years of life. Frequently infection becomes chronic. The risk of developing HCC is higher in 
the presence of cirrhosis, obesity and diabetes mellitus, and co-infection with hepatitis C virus. 
Factors associated with a high risk of HCC include demographic (male sex and age), lifestyle 
(alcoholism and smoking), viral (genotype C, D, and F, elevated level of HBV-DNA, 
nucleus/mutation pre-core) and clinical liver cirrhosis, elevation of alpha-fetoprotein (AFP), and 
alanine aminotransferase (ALT) characteristics. Although the incidence of chronic hepatitis B 
has been falling as a result of universal infant immunization, the incidence of HBV induced 
HCC will increase for about two more decades. HCC related to HBV has a bad prognosis with 
average survival below 16 months (14, 15, 17-21). 
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Approximately 6-10% of individuals infected with HIV are more likely to be infected with 
HBV, an estimated 2.5 to 3 million people. Studies show that HIV infection impacts negatively 
on the evolution of hepatitis, resulting in a higher rate of chronicity of HBV after acute infection, 
by increasing the replication rate of DNA-HBV and exacerbates fibrosis, a lower rate of 
Hepatitis B e Antigen (HBeAg) seroconversion and a higher percentage of occult infections, 
which presents serious problems for diagnosis, prevention and control. The presence of co-
infection also worsens the outcome of HBV infection treatment  (22, 23).  
 
It has been demonstrated that HLA-A (Human Leucocytes Antigen -A) genotype is 
dominant in mediating control of HBV DNA, predicting HBeAg-positive status. This finding 
supports the role of CD8+ T cell response in HBV control. The relationship was not significant 
for HLA-B or HLA-C alleles, the other two human types of Major Histocompatibility Complex 
(MHC) class I (24).  
 
About 25% (10 million) of HIV infected patients are estimated to also be infected with 
the Hepatitis C Virus (HCV). There is no consensus about the negative effect of HIV infection 
on the evolution of hepatitis caused by HCV. Nevertheless, it possibly increases RNA HCV by 
accelerating the progression of fibrosis and increasing the rate of chronicity of HCV, thereby 
facilitating the sexual and vertical transmission of the virus (22). 
 
In many countries worldwide chronic liver disease caused by infection with HBV and/or 
HCV in HIV-infected patients is common, making it one of the causes of morbidity and mortality 
among HIV-infected people. The co-infection in HIV patients with HCV is particularly high in 
areas where intravenous drug use is high (25, 26). 
 
The prevalence of HCV infection in pregnant women is estimated to be between 1 and 
8%, in children between 0.05% and 5%, worldwide. Parenteral transmission is still common in 
children living in developing countries and HIV co-infection is associated with increased 
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transmission. In developed countries, perinatal transmission is now the leading cause of HCV 
transmission (27). 
 
The absence of an HCV vaccine or approved therapy during pregnancy means that 
prevention of vertical transmission is still not possible. However, a low vertical transmission 
rate of 3-5%, a high rate of spontaneous clearance (25-50%) and delayed morbidity have 
resulted in HCV being overlooked in pregnant women and their infants. Factors known to 
increase the risk of perinatal transmission include HIV co-infection and higher maternal viral 
loads. Current guidelines for the diagnosis of persistent perinatal infection require a positive 
anti-HCV test in infants born to infected mothers after 12 months or two positive HCV RNA 
tests at least 6 months apart (27, 28).  
 
Syphilis is a major public health problem in sub-Saharan Africa, a study conducted 
among pregnant women, found a high prevalence of syphilis and coinfection of HIV/Syphilis 
the rate was high. The prevalence of syphilis and HIV has been shown to vary by time period, 
geographic area and study population (12, 29-32). Untreated syphilis during pregnancy is 
associated with the incidence of adverse pregnancy outcomes such as congenital syphilis, 
stillbirth, miscarriage, neonatal death and low birth weight (33) The risk for syphilis infection is 
significantly higher among women with more than 3 previous pregnancies and those attending 
semi-urban and rural clinics (34).  
 
In Mozambique, a study conducted in 1578 replacement blood donors in Maputo 
Central Hospital, showed an HBsAg seroprevalence in men and women, of 10.6% and 4.5%, 
respectively, and an Anti-HCV seroprevalence of 1.2% and 1.0 %, respectively (35). Another 
study, conducted in four rural clinics in northern Mozambique among HIV positive individuals, 
revealed a prevalence of 7.6% HBsAg-positive. (36).  An earlier study conducted on 428 
Mozambican refugees in South Africa for markers of exposure of HBV and HCV, showed that 
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56% of the population had anti-HBsAg, while 13.2% were also HBeAg positive and 3.2% were 
anti-HCV positive (37). 
 
The risk of HCV infection remains very low in Mozambique. In a recent study among 
voluntary and replacement blood donors, in the Provincial Hospital of Tete, no HCV infection 
was found. Prevalence for infection by HIV, HBsAg and syphilis were 8.5%, 10.6% and 1, 2%, 
respectively (38). 
 
From the beginning of the HIV epidemic, Mozambique developed strategic plans that 
included prevention strategies. Priorities include the treatment of opportunistic diseases and 
AIDS disease manifestations (39), taking into account the criteria of the World Health 
Organization (WHO) on access to antiretroviral treatment, and assuming the limitations of 
human, financial and responsiveness of the National Health System (40). 
 
A study conducted among pregnant women, in Nigeria, showed a high prevalence of 
HIV, HBV and HIV-HBV co-infection. Widowed/divorced women had a higher prevalence of 
HIV, HBV infection (P<0.001), and more educated women had a lower prevalence of HBV 
infection. The rates of co-infection were higher among students as compared to other 
occupations (41). HIV plays an important role on HBV transmission: a study conducted in 
Mozambique and Zambia among HIV positive individuals, showed  high median HBV viral 
loads, and CD4 cells count below 200/μl, HBeAg-positivity was  associated with high HBV DNA 
(>20,000 IU/ml), and genotypes A1 (58.8%) and E (38.2%) were most prevalent (36).   
 
Mother-to-child transmission (MTCT) of HCV is not a major route of HCV transmission. 
In a study conducted in Cameroon 68 (76%) out of 89 ant-HCV positive pregnant women were 
HCV-RNA positive. Genotype 4 was predominant (43%), followed by genotypes 1 (28.1%) and 
2 (26.6%). Among 35 women who delivered 36 live children, none of those screened at 6 
weeks and 6 months were HCV-RNA positive (42). Although the influence of HIV and HCV co-
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infection depends on the CD4 counts, with a relative risk for the development of cirrhosis of 
about two, HBV/HCV co-infection is uncommon the co-infected patients have a higher risk of 
developing HCC than those who are only infected with one virus (43). 
 
In 2009, an estimated 370 000 children [220 000 – 520 000] contracted HIV during the 
perinatal and breastfeeding period, although these numbers have shown a diminution in the 
number of infected children compared with the year 2001. In 2010, UNAIDS began a campaign 
for the virtual elimination of mother to child transmission of HIV by 2015, in the 10 most severely 
affected countries. They considered this to be a realistic aim, which could be achieved with a 
significant increase in the implementation of proven strategies to eliminate HIV transmission 
to children (44).  
 
Intimate partner violence (IPV) is a major public health problem in Africa and worldwide 
(45). A systematic review of African studies on IPV during pregnancy has shown a prevalence 
range from 2% to 57% (46).  Women account for a rising percentage of all HIV cases, with 
husbands' risky behavior described as the major source of women's infection. Women who 
have experienced physical abuse during pregnancy have an increased risk of preterm delivery, 
independently of a large set of behavior and sociodemographic characteristics, recognized as 
associated factors for preterm birth (47). Furthermore, women who are taking antiretroviral 
drugs for HIV treatment are more likely to suffer any type of intimate partner violence (physical, 
sexual or psychological) (48-51). In rural Uganda, almost one in three women living with HIV 
had suffered intimate partner violence in the preceding 12 months. Nearly one in five HIV 
patients reported physical violence, and about one in every seven HIV patients reported 
sexual/psychological violence (48). A similar pattern was also reported in Rwanda, where HIV 
positive participants were more than twice as likely to report physical IPV compared to those 
who were HIV negative (52). These findings highlight the interaction between gender 
inequality, domestic violence and HIV infection (53). Moreover, a systematic review of studies 
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conducted in Africa has shown a significant association between HIV and IPV during 
pregnancy (54).  
 
A cohort study in South Africa showed that 13.9% of incident HIV infection could be 
averted if women were not in a relationship of low power and 11.9% of new HIV infection could 
be averted if women did not experience more than one episode of physical or sexual partner 
violence (55). Cohort studies of incident HIV/Sexual Transmitted Infections (STI) have found 
an increased risk of HIV/STI among women exposed to IPV (56). 
 
A gender-related vulnerability has been recognized as a key aspect contributing to the 
increased propensity for women to contract HIV. Negotiations surrounding sexual activity are 
characterized by multiple power disparities that include race, social status, and age, with 
gender being the most dominant differential in heterosexual interactions. This pressure and 
coercion or manipulation is felt by women in interactions either with older men or in their 
romantic partnerships. Some of their counterparts experienced pressure to engage in sexual 
intercourse with their boyfriends when they were unwilling or unready, and they reported being 
faced with additional pressure to engage in unprotected sex (57). A community cohort study in 
Uganda showed that risk factors for physical or sexual violence, include younger age, being 
married, relationships of shorter duration, having a partner who is the same age or younger, 
alcohol use before sex by women and by their partners, and thinking that violence is 
acceptable. Nonetheless, HIV infection and pregnancy were not associated with increased 
odds of IPV (58). In Zimbabwe, the rates of IPV during pregnancy are among the highest ever 
reported globally (59). 
 
The WHO review identified risk factors for IPV and classified them into four levels of an 
ecological framework: individual, relationship, community and societal levels factors (60). 
Individual-level factors are younger age, lower socio-economic status, lower levels of 
education, separation or divorce, pregnancy, exposure to intra-parental violence in childhood, 
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sexual abuse, depression, harmful use of alcohol or illicit drugs, acceptance of violence, and 
exposure to prior abuse or victimization.  Relationship level factors are an educational disparity, 
a greater number of children, and marital dissatisfaction or discord. Community level factors 
are acceptance of traditional gender roles, unemployment, poverty, a high female illiteracy 
rate, acceptance of violence, a low proportion of women with high level of autonomy, a low 
proportion of women with higher education, and weak community sanctions (i.e. communities) 
which lack legal sanctions and where women lack access to shelters and family support, and 
in which there is less moral pressure for neighbours to intervene if a woman is beaten). Societal 
level factors are divorce regulations, a lack of legislation on IPV within marriage, protective 
marriage laws, and traditional gender and social norms (60, 61). 
 
Syphilis and IPV disproportionally affect women and may be associated. A study 
conducted in Bolivia showed that 20.4% of women who reported IPV had a positive Syphilis 
test, compared to 4% in women who did not report IPV (46). 
 
Routine antenatal HBV screening should be offered in HIV/HBV endemic regions, 
especially for HIV-positive pregnant women, to allow the identification of neonates who are in 
need of HBV passive immunoprophylaxis at birth. This strategy, together with antenatal 
antiretrovirals, will contribute to reducing the risk of perinatal HBV transmission (62). To reduce 
the risk of infection of the mothers, the appropriate emphasis should be given to increasing 
awareness and intensive public health education about the horizontal transmission HBV (63, 
64). In Mozambique a report from the National Health System (NHS), the percentage of women 
with at least one prenatal consultation had been increasing in recent years, reaching 91% of 
pregnant women, in 2012 (65). 
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2. STUDY RATIONALE 
 
Mozambique is among the 10 countries with the highest prevalence of HIV and number 
of AIDS patients (2). With the expansion of antiretroviral therapy, AIDS has increasingly 
become a chronic disease, rather than a cause of death. People infected with HIV now have 
increased life expectancy and quality of life of. Expanding access to ART is part of government 
policy in Mozambique, it can be sustained by the Ministry of Health approval of a new therapy 
that introduced Tenofovir (TDF), a drug with effective action for the treatment of HBV co-
infection (40).  
 
Global Knowledge regarding the prevention of HIV transmission has increased, 
condom use has risen amongst people with multiple sexual partners and the proportion of 
young people who have received an HIV test and learned their results has also increased. 
Countries now also have the potential to reach at least 90% of pregnant women living with HIV 
with antiretroviral interventions by 2015 (66). 
 
MTCT of HIV infection continue to be a major public health problem and is the most 
important cause of HIV infection in children under the age of 15 years old, hence, strengthening 
the level of PMTCT services in ANC settings and devising mechanisms to promote involvement 
of men in PMTCT services is needed to increase the low awareness and knowledge on timing 
of MTCT of HIV (67). Prevention of MTCT of HBV continues to be a challenge in most SSA 
countries, where more than 8% of the population remain chronic carriers of HBV, despite the 
implementation of HBV birth-dose vaccination. The  HBV vaccine coverage remains low (68). 
 
The efficiency of HIV transmission male-to-female is 2.3 times greater than female-to-
male transmission, during the sexual intercourse, are possible reasons for the difference in 
efficiency of transmission (69, 70). The involvement of men in antenatal care could potentially 
prevent women from acquiring HIV infection during pregnancy and post-partum when they are 
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more vulnerable and have a high risk of transmission to the infant. (71). Pregnant women need 
to be informed of their increased risk of HIV, HBV, the importance of reduction of sexual activity 
during pregnancy and the need to use condoms throughout pregnancy and identifying the 
significant challenges to implementation of either HIV and/or HBV prevention programs, 
especially during antenatal visits (68, 71, 72).  
 
Syphilis is a public health problem in Mozambique, studies conducted among pregnant 
women and STD patients, from 1985 to 2000, the prevalence varied from 4.5% to 15% (73-
76). A National Antenatal HIV and Syphilis Surveillance Survey found, in 2011, a national 
syphilis prevalence of 2.2% and in the northern region of the country the prevalence was 8.2% 
(77). 
 
Due to the shared route of transmission for HIV, HBV, HCV and syphilis, adequate 
knowledge and prevention of mother to child transmission could contribute to a reduction of 
the burden of HIV, HBV, HCV and syphilis infection among children (7, 33, 78).  
 
IPV and gender inequity in relationships are associated with increased incidence of HIV 
in women. A cohort study of young women, in South Africa, showed that women who reported 
more than one episode of IPV at baseline were likely to acquired HIV (9·6 per 100 person-
years) compared with 83 of 846 who reported one or no episodes (5·2 per 100 person-years). 
Relationship power inequity and IPV increase the risk of incident HIV infection in young women 
(55). 
 
Information and communications technology are contributing dramatically to alter the 
ways in which people network, interact, communicate and share information. They could offer 
new opportunities to expand structured programs which can increase the leveraging of new 
information tools to improve women’s health  (66). 
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The knowledge and attitudes regarding HIV, HBV, and HCV of pregnant women in the 
context of Nampula are not known. The IPV among pregnant women and its various 
consequence still need to be investigated, to enable the health system to build up strategies 
which can increase the awareness among pregnant women, in Nampula, Mozambique. 
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3. RESEARCH QUESTIONS 
 
1. What factors are associated with HIV, HBV, HCV and Syphilis co-infection among pregnant 
women, and people living with HIV, in Nampula? 
2. What could be the contribution of Intimate Partner Violence (IPV) among women on HIV, 
HBV, HCV and Syphilis infection?  
 
3.1. Objectives 
 
3.1.1. General objective 
To assess the knowledge of and attitudes regarding HIV, HBV, HCV and Syphilis, the 
prevalence of co-infection among pregnant women and people living with HIV, and the 
frequency of IPV in pregnant women, in Nampula city, Mozambique. 
 
 
3.1.2 Specific objectives 
1. To describe the frequency, dynamics and risk factors associated with intimate 
partner violence among pregnant women. 
2. To assess knowledge and attitudes regarding HIV, HBV and HCV infection in 
pregnant women attending antenatal clinics. 
3. To assess knowledge and attitudes regarding HIV, HBV and HCV infection in 
people living with HIV. 
4. To assess the prevalence of HIV, HBV, HCV and Syphilis co-infection among 
pregnant women and HIV patients. 
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4. METHODS  
 
4.1 Setting and study population 
 
The research was cross-sectional, carried out in six urban health units in Nampula City, 
Mozambique, offering antenatal care services, namely the Hospital Geral de Marrere, Centro 
de Saúde 25 de Setembro, Centro de Saúde do Hospital Psíquiátrico, Centro de Saúde 1º de 
Maio, Centro de Saúde de Namicopo and Centro de Saúde de Muhala Expansão, from 
February 2013 to January 2014. 
 
A sampling procedure was consisting of inviting to participate in the study, one in every 
three pregnant women attending the six health facilities for their first prenatal appointment. In 
total, 1440 pregnant women were invited to participate and 1216 (84.4%) agreed to participate. 
After informed consent of 1216 pregnant women, only 946 pregnant women were or have had 
in a relationship lasting more than 1 month and therefore eligible to answer the Conflict Tactics 
Scale 2 and other questions for Intimate Partner Violence (IPV). Of the 946 women, 77 were 
excluded from the analysis due to missing information on violence measures. Therefore, 869 
women were included in the final analysis (only 40 women were not already in the relationship). 
 
A similar sampling procedure was performed for all HIV and AIDS patients attending 
antiretroviral clinics. A total of 761 were invited to participate and 742 (97.5%) agreed to 
participate.  
 
During transportation from Nampula to Maputo, 550 plasma samples out of the 1216 
samples collected from pregnant women were lost. Thus 666 (54.8%) samples were included 
in the final laboratory analysis. Almost 413 plasma samples of HIV and AIDS patients were 
also lost, leaving 279 (40.3%) of plasma samples which were used to perform the tests of 
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Hepatitis B virus analysis. For Hepatitis C analysis, the samples were able to perform 235 
(34.0%). 
In each health facility, nurses for maternal and child health, health officer and university 
students were trained to conduct the interviews using a structured questionnaire. After training 
the nurses, health officer and university students carried out a pilot study, which allowed further 
familiarization with the questionnaire, as well as harmonizing the flow of questions.  
 
Collection of Blood samples  
The blood samples were collected using the current procedures at health units, 
established by the National Health Services (NHS). All were analyzed following standard 
procedures for laboratory tests. Analyses that were not part of the routine (hepatitis B and C) 
were performed later on the sera collected for biochemical analysis at the laboratory of the 
National Institute of Health, Ministry of Health. 
Plasma samples of pregnant women and HIV patients were collected and kept frozen 
at −80°C until analysis. 
 
4.2 Measures 
 
Questionnaire and measurement tools 
Face-to-face interviews were conducted, and data were collected using structured 
questionnaires administered by trained nurses, health officers, and university students, and 
directed to pregnant women and HIV patients. The questionnaire included questions related 
to sociodemographic information (age, sex, marital status, occupation, education) - use of 
alcohol, tobacco and illegal drugs use, sexual behavior (age at the first intercourse, number of 
sexual partners in the last 6 months), gestational age at the first appointment, history of 
neonatal deaths, and also diagnosis of sexually transmitted infections and non-prescribed pills, 
information on maternal health (weight, gestational age, parity and history of abortion), 
information on sexual health (age at 1st sexual intercourse, type of partner and condom use in 
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the last sexual intercourse, other sexual partners), history of non-sexual exposures to HIV, 
HBV, HCV, knowledge regarding HIV/AIDS, HBV, HCV modes of transmission and knowledge 
regarding other sexually transmitted infections (STIs), history of HIV, HBV, HCV, STI and 
tuberculosis. The data were double-checked for accuracy on entry to the database. 
 
The collection of blood samples and clinical files, established by the NHS, was part of 
the normal procedures at health unit. The study included data on HIV test results, CD4 T cells 
count, serology for hepatitis B (immunoserology screening biomarker of HBsAg, HBeAg, anti-
HBc, HBcAg) and hepatitis C (anti-HCV) and syphilis test, including liver transaminases, these 
were assessed following standard procedures, which will be described on laboratory chapter. 
Analyses that were not part of the routine (hepatitis B and C) were obtained using the serum 
collected for biochemical analysis and performed at the Nampula Central Hospital laboratory.  
 
IPV was assessed using the conflict tactics scales (CTS2) (79). The women were asked 
whether they had been victims of various types of IPV. The CTS2 covers psychological 
aggression, physical assault, sexual coercion, physical assault with injury). The acts may have 
occurred once, twice, 35, 6-10, 11-20 or 20 times during the past year, had not occurred during 
the past year/but before or never occurred.  
 
Data analyses 
For analysis of IPV, maternal age was categorized into five categories (>18, 18-20, 21-
25, 26-29, ≥30 years), education was categorized according to the Mozambique education 
system (no education/did not finish primary school, primary school including the first and 
second degree, secondary school, and pre-university and university degree), marital status 
was considered aggregating married or in cohabitation vs. single or separated) and occupation 
classified in three categories that were the most frequently reported by women: housewife or 
unemployed, employed or farmer, and student. 
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In this analysis, we only used severe or minor physical assault acts (e.g. beat up) and 
severe/minor sexual coercion acts (e.g. threaten to have sex) and severe/minor injury (e.g. 
bruises). For the present analysis, we consider that women had been abused during the past 
year if they disclose at least one occurrence of abuse during the past year independently of 
chronicity. 
 
Information was obtained on age at first sexual intercourse (and then coded as ≤14, 
15-19, >19 years), and sexual intercourse during the last 6 months, coded as Yes or No. Parity 
was classified as 0, 1, 2, 3, 4 or more, the gestational age at the first antenatal clinic 
appointment (coded as ≤14 weeks, 15-27 weeks, ≥28 weeks, roughly corresponding to 
trimesters), and history of neonatal deaths. Women were categorized as primigravidae, 
multigravidae with no neonatal deaths and multigravidae with neonatal deaths. Women were 
also asked about a previous diagnosis of HIV, syphilis, and gonorrhea. 
 
Statistical analysis 
All data were double-checked for accuracy on entry into the database. The Chi-square 
test was used to compare proportions. Significance associations were tested using a p-value 
< 0.05. The odds ratio (OR) and respective 95% confidence intervals (95%CI) were calculated 
through Logistic Regression, with adjustment for the potential confounders. The data analysis 
was performed using the statistical software SPSS, version 22. 
 
Latent Class Models (LCM) was used to identify groups/patterns in terms of knowledge 
about HIV, HBV and HCV modes of transmission. LCM was used given the binary structure of 
the data. LCM solutions with 1, 2 and 3 classes were tested from which we chose the one that 
showed the smallest Bayesian information criterion (BIC) and the smallest Akaike’s Information 
Criterion (AIC).  
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Interpretation of the model is usually done by looking at the probabilities of correct 
answers on each item conditional on class membership.  
 
Comparisons of proportions by latent classes were performed using the chi-square test 
or Fisher’s exact test, as appropriate. To test the differences between the observed and the 
expected cases in each cell we used the absolute adjusted residuals higher than Z1-α/2; α 
defined with Bonferroni correction. A significance level was fixed at 0.05. Comparisons 
between groups were performed using the SPSS software for Windows, version 22.0 (SPSS 
Inc., Chicago, Illinois, USA). LCM was performed using the software R 2.8.1, specifically the 
poLCA package.  
 
4.3 Laboratory 
 
Screening of Biomarkers for HBV 
Plasma samples of HIV-infected patients and pregnant women were collected and kept 
frozen at −80°C until further analysis. 
 
The immunoserology screening biomarker of HBsAg in plasma samples was measured 
using an immunoenzimatic 4th generation test, MP Diagnostics HBsAg ELISA 4.0, according 
to the manufacturer's procedures (MP Biomedicals Asia Pacific Pte Ltd, Singapore). The 
immunoserology diagnosis of biomarker HBeAg in plasma samples was performed using an 
enzyme immunoassay 4th generation test, 4.0 MP Diagnostic HBeAg ELISA, following the 
procedures indicated by the manufacturer (MP Biomedicals Asia Pacific Pte Ltd, Singapore). 
The immunoserology screening of anti- HBc, an antibody to HBV core antigen (HBcAg) in 
plasma samples, was performed using an enzyme immunoassay 4th generation diagnostic 
MP 4.0 Anti -HBc ELISA (MP Biomedicals Asia Pacific Pte, Ltd, Singapore).  
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Finally, the immunoserologic diagnosis of anti-HBs, antibody to the surface antigen of 
HBV (HBsAg), in plasma samples was conducted using a 4th generation immunoenzimatic 
test, MP Diagnostic Anti-HBs ELISA 4.0, according to the manufacturer's procedures test (MP 
Biomedicals Asia Pacific Pte, Ltd, Singapore). 
 
Screening for HCV 
The immunoserologic diagnosis for the presence of HCV was done by a screening of 
anti-HCV in plasma samples using an enzyme immunoassay 3rd generation HCV ELISA 3.0 
MP Diagnostic and following the manufacturer's instructions (MP Biomedicals Asia Pacific Pte, 
Ltd, Singapore). The presence of anti -HCV antibodies in plasma samples was indicative of 
infection by hepatitis C. 
 
Screening for HIV 
The biomarkers screening for the presence of HIV was made using two immunoassays 
4th generation with the capacity to detect antibodies and antigens of HIV. The initial HIV 
screening was performed using the immunoassay test Vironostika HIV Ag/Ab (Biomerieux SA, 
Marcy l' Etoile, France). All samples with reactive results to antibodies and to HIV antigens 
were retested using a second immunoenzimatic assay, MP Diagnostics HIV Ag/Ab Combo 
ELISA 4.0, according to the manufacturer's procedures (MP Biomedicals Asia Pacific Pte Ltd, 
Singapore). The HIV positive result indicating the presence of HIV was considered when the 
sample had a reactive result in the first and second tests respectively. Those showing a non-
reactive result of the first test were classified as seronegative for HIV. Those having a non-
reactive result in the second test, the third test was performed using the second 
immunoenzimatic assay. If the result were reactive, the samples were classified as being 
seropositive for HIV, and if the result was non-reactive, the samples were classified as 
seronegative. There were a few samples that were classified as having indeterminate results 
due to insufficient plasma to complete the testing procedures. See below diagram of the 
algorithm for the laboratory diagnosis of HIV. 
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Screening for Syphilis 
The syphilis serologic test is used to detect antibodies against Treponema Pallidum the 
causative agent of syphilis. Two groups of antibodies are searched for. The first group is 
antibodies against non-treponema antigens, such as the lipid structures (phospholipids), 
resulting from infection by the organism T. pallidum. Screening can be performed by a test 
using RPR (Rapid Plasma Reagin). This test is relatively nonspecific, especially in titles lower 
than 1/16. The result can characterize a false-positive reaction, occurring in individuals with 
autoimmune diseases, malaria, viral and bacterial infections, and even pregnant women. Titres 
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higher than 1/16 are suggestive of Treponema pallidum infection. The RPR is useful in the 
therapeutic segment, becoming positive 2 to 3 weeks after the patient has been infected. 
 
The second type of antibody is directed against components of the Treponema and 
can be performed using the FTA-ABS test (fluorescent treponemal antibody absorption), the 
TPHA test (Treponema pallidum Haemagglutination) and TPPA test (T. pallidum agglutination) 
the last test is used in the reference laboratory for microbiology. The previous tests are 
considered confirmatory for syphilis diagnosis when the RPR test is positive. 
 
Patients with Syphilis, after treatment, may have persistent positive reactions in the 
RPR (lower titers, equal to or less than 1/8), without clinical significance, which are recognized 
as serological scars. 
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RPR (Rapid Plasma Reagin) 
Rapid test for the qualitative and quantitative detection of syphilis serum or plasma. 
The RPR is a nontreponemal technique for the rapid diagnosis of syphilis. The RPR antigen is 
a modification of the VDRL antigen containing additives to eliminate the need for inactivation 
of the serum to increase the suspension stability and to facilitate visual reading of the reaction. 
 
The antigen of RPR is a cardiolipínica suspension containing microparticles of coal. 
This antibody detects an antigen, termed reagin, which is present in the serum of patients with 
syphilis. If there are antibodies in the sample (reagins), they react with the antigen to form a 
complex with the coal microparticles coagulate, forming black lumps whose size depends on 
the sample. If the reaction is negative, the reaction remains mixture unchanged, showing, in 
this case, a homogeneous grey color. 
 
Test procedures and interpretation of the results 
Qualitative test: The screening tests were performed according to the description on the 
manuals of qualitative methods procedures. The interpretation of the results was made from 
the presence of aggregates of carbon black around the edge was reported as RPR Positive. 
The presence of small aggregates of carbon black around the edge was reported as weak 
positive RPR. The absence of aggregates was reported as negative RPR. 
 
Quantitative Test: The tests were performed according to the procedures described in the 
manual of screening for the quantitative methods. The interpretation of the results was reported 
from the coefficient of dilution that still represents clearly the Reactive Result: Positive RPR + 
coefficient of dilution. Titles greater than 1/16 were suggestive of Treponema infection. 
 
The confirmation of the results was made using the TPPA test. 
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4.4 Ethical clearances 
 
The study was approved by the Ministry of Health and by the National Bioethics 
Committee of Mozambique. All measures were taken to ensure confidentiality and not to 
change the normal service procedures. The interviews were administered in a consultation 
office, where pregnant women followed all the clinically recommended procedures. All 
participants gave their written informed consent prior to inclusion.
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5. RESULTS  
5.1 HIV and Viral Hepatitis B, C in Mozambique (paper I). 
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Abstract: 
 
Introduction: Mozambique is one of the most affected countries by the AIDS epidemic in the 
world, with an HIV prevalence of 11.5% in the 15-49-year age group. Due to the shared mode 
of transmission, coinfection with Hepatitis B (HBV) and C (HCV) are common, in Africa 
particularly in Mozambique. The study aims to assess the prevalence of HIV, HBV and HCV 
coinfection in Mozambique. 
Methods: From January 1996 to April 2016, we searched the literature for articles that 
assessed the prevalence of HIV, HBV or HCV infection and coinfection, in Mozambique. We 
searched multiple English and Portuguese electronic data sources including PubMed and 
Google Scholar. Keywords that we used for our search were “HIV and HBV”, “HIV and HCV”, 
“HIV and viral hepatitis” and “coinfection and HIV”. Studies that reported HIV, HBV or HCV 
infection were also included. 
Results: Few HIV, HBV, and HCV prevalence studies conducted in Mozambique, were 
performed on HIV-positive blood recipients from refugees in Mozambique from neighboring 
countries such as South Africa and Swaziland; only one study was done on the health of young 
people, in Maputo. 
Conclusion: The prevalence of HIV and HBV is higher and, HCV remains with low prevalence 
in Mozambique. HBV may also have been transmitted vertical in children, and screening for 
HBsAg could contribute substantially to avert the negative impact on morbidity and mortality 
of HIV/HBV coinfected individuals.  
 
 
Keywords: Human immunodeficiency virus (HIV), hepatitis B virus (HBV), hepatitis C virus 
(HCV), and viral hepatitis coinfections in Mozambique.  
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Introduction 
The Human Immunodeficiency Virus (HIV) and the Acquired Immunodeficiency 
Syndrome (AIDS) pandemic continuous to be a cause for worldwide concern. Presently 
estimates show that 36.9 million people were living with HIV and AIDS, some 2 million were 
newly infected people and the number of deaths related of AIDS illness was 1.2 million 
worldwide (1). The HIV/AIDS epidemic poses a challenge to the Sub-Saharan Africa, particular 
in Mozambique (80), the countries most affected by the pandemic, with an HIV  prevalence of 
11.5% in the 15-49 year age group (5, 6). 
Globally, estimates show that of all people living with HIV worldwide, about 2 - 4 million 
also have Hepatitis B Virus (HBV) infection and 4 – 5 million people Hepatitis C virus (HCV) 
infection (2). HIV is associated with a higher prevalence of both HBV and HCV in Sub-Saharan 
Africa. A systematic review and meta-analysis of people infected with HIV showed Hepatitis B 
surface Antigen (HBsAg) and antibodies to Hepatitis C Virus (anti-HCV) prevalence of 15% 
and 7%, respectively. The risk ratios (RRs) for being HBsAg positive and anti-HCV positive 
were 1,40 and 1.60 in HIV-infected, as compared to HIV-uninfected patients (7).  
An estimated 350 million people are chronically infected with HBV and are at risk of 
developing hepatocellular carcinoma (HCC), with over 2 billion individuals being exposed to 
the virus (13). Chronic infection with HBV is the most frequent cause of this type of a tumour, 
representing more than 50% of global cases. In HCC endemic regions, this number rises to 
almost 70 - 80% of the cases, becoming the sixth most common type of cancer today. The 
incidence of HCC among individuals with chronic HBV infection ranges from 400 to 800 in 
males and from 120 to 180 in females, per 100.000 persons/year. Approximately 80% of HCCs 
cases occur in developing countries in regions such as the Asia-Pacific and Sub-Saharan 
Africa where HBV infection is endemic and has a high incidence (14, 15). 
The Sub-Saharan Africa Coinfections Panorama 
In Africa, about 50 million people are a chronic carrier of HBV, with 25% of mortality 
risk. The Sub-Saharan Africa countries are in a high endemicity region with HBsAg carrier 
rates between 9 – 20% (16). 
32 
 
HBV infection is acquired during the prenatal period, at birth or during the first months 
or years of life. Frequently infection becomes chronic. The risk of developing HCC is higher in 
the presence of cirrhosis, obesity and diabetes mellitus, and co-infection with hepatitis C virus. 
It has been identified factors associated with a high risk of HCC include demographic (male 
sex and age), lifestyle (alcoholism and smoking), viral (genotype C, D, and F, an elevated level 
of HBV-DNA, nucleus/mutation pre-core) and clinical liver cirrhosis and other factors. Although 
the incidence of chronic hepatitis B has been falling as a result of universal infant immunization 
(14, 15, 17-21). 
Approximately 6-10% of individuals infected with HIV are more likely to be infected with 
HBV, an estimated 2.5 - 3 million people. Studies show that HIV infection impacts negatively 
on the evolution of hepatitis, resulting in a higher rate of chronicity of HBV after acute infection, 
by increasing the replication rate of DNA-HBV and exacerbates fibrosis, a lower rate of 
Hepatitis B e Antigen (HBeAg) seroconversion and a higher percentage of occult infections, 
which presents serious problems for diagnosis, prevention and control. The presence of co-
infection also worsens the outcome of HBV infection treatment  (22, 23).  
About 25% (10 million) of HIV infected patients are estimated to also be infected with 
the Hepatitis C Virus (HCV). There is no consensus about the negative effect of HIV infection 
on the evolution of hepatitis caused by HCV. Nevertheless, it possibly increases RNA HCV by 
accelerating the progression of fibrosis and increasing the rate of chronicity of HCV, thereby 
facilitating the sexual and vertical transmission of the virus (22). 
In many countries worldwide chronic liver disease caused by infection with HBV and/or 
HCV in HIV-infected patients is common, making it one of the causes of morbidity and mortality 
among HIV-infected people. The coinfection in HIV patients with HCV is particularly high in 
areas where intravenous drug use is high (25, 26). 
The prevalence of HCV infection in pregnant women is estimated to be between 1 -8%, 
in children between 0.05% - 5%, worldwide. In developed countries, perinatal transmission is 
now the leading cause of HCV transmission and HIV coinfection is associated with increased 
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transmission (27). Mother-to-child transmission (MTCT) of HCV is not a major route of HCV 
transmission (42, 43). 
HIV plays an important role on HBV transmission: a study conducted in Mozambique 
and Zambia among HIV positive individuals, showed  high median HBV viral loads, and CD4 
cells count below 200/μl, HBeAg-positivity was  associated with high HBV DNA (>20,000 
IU/ml), and genotypes A1 (58.8%) and E (38.2%) were most prevalent (36).   
Routine antenatal HBV screening should be offered in HIV/HBV endemic regions, 
especially for HIV-positive pregnant women, to allow the identification of neonates who are in 
need of HBV passive immunoprophylaxis at birth. This strategy, together with antenatal 
antiretrovirals, will contribute to reducing the risk of perinatal HBV transmission (62). To reduce 
the risk of infection of the mothers, the appropriate emphasis should be given to increasing 
awareness and intensive public health education about the horizontal transmission HBV (63, 
64). In Mozambique a report from the National Health System (NHS), showed that the 
percentage of women with at least one prenatal consultation had been increasing in recent 
years, reaching 91% of pregnant women, in 2012 (65). 
The efficiency of HIV transmission male-to-female is 2.3 times greater than female-to-
male transmission, during the sexual intercourse, are possible reasons for the difference in 
efficiency of transmission (69, 70). 
Global Knowledge regarding the prevention of HIV transmission has increased, 
condom use has risen amongst people with multiple sexual partners and the proportion of 
young people who have received an HIV test and learned their results has also increased. 
Countries now also have the potential to reach at least 90% of pregnant women living with HIV 
with antiretroviral interventions by 2015 (66). 
Objective: To assess the prevalence of HIV, HBV and HCV coinfection in Mozambique. 
 
Methods 
Information sources and search 
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We searched the literature, from inception, for articles that assessed the prevalence of 
HIV, HBV or HCV infection and coinfection. Between September and October 2017, we 
searched PubMed. 
We reviewed the titles and abstracts to select potentially and relevant papers. The full 
text was reviewed only if there was a doubt about the suitability of the paper based on the 
abstract. For inclusion, we searched electronic abstracts from articles conducted in 
Mozambique. 
The expression used for our search was ((HIV AND HBV) OR (HIV AND HCV) OR (HIV 
AND viral hepatitis) OR (coinfection AND HIV)) AND Mozambique.  
 
Eligibility criteria and study selection 
We only included studies that recruited participants living in Mozambique, published in 
English or Portuguese, measured HIV (HIV Ab), HBV (HBs Ag) or HCV (HCV Ab) infection and 
coinfection. We excluded studies with 1) no accessible full text and no sufficient data in 
abstract, 2) unclear serological tests to detect the three infections.  
 
Data collection and Analytic Approach 
Data were extracted and checked for the following items: type of study, sample size, 
location and time of the study, type of participants and prevalence of HIV, HBV, HCV, and 
coinfections. We grouped the participants into four subpopulations 1) Replacements blood 
donors, 2) patients with HIV infection, 3) Refugees and 4) general population. The outcome of 
the studies was reported as prevalence, with point and 95% confidence intervals.  
 
Results 
We found 43 abstracts in our literature review. After screening of title and abstract 25 
remained for full-text review. Of those, 17 articles were excluded for various reasons including: 
no report of coinfection; full text was not available; other scientific field of study, such as 
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molecular, cost economic; and specific subpopulations not listed in the four population 
categories we have chosen. 
 
According to the table 1, which describe the results of the studies conducted in 
Mozambique, among 1578 replacement blood donors, HBsAg seroprevalences in men and 
women are 10.6% and 4.5%, respectively, and an Anti-HCV seroprevalence of 1.2% and 1.0 
%, respectively (35). In a recent study among voluntary and replacement blood donors, in the 
Provincial Hospital of Tete, no HCV infection was found. The prevalence for infection by HIV, 
HBsAg, and syphilis were 8.5%, 10.6%, and 1,2% respectively (38). Another study conducted 
between HCC and HCV, sera from 178 patients with HCC and 194 from Maputo blood donors, 
were tested from Anti-HCV, showing the higher prevalence of Anti-HCV in patients with HCC 
than in the controls but there was a negative association between Anti-HCV and HBsAg in 
patients with HCC, that was not significant after adjustments for age (81). A study conducted 
among 2019 blood donors, fund a prevalence of HIV and HBsAg 5.7% and 6.0%, respectively 
(82). 
A study conducted in four rural clinics in northern Mozambique among HIV positive 
individuals, revealed a prevalence of 7.6% HBsAg-positive (36), another study conducted in 
two health centres in Maputo, on 518 HIV infected with and without HBV co-infection naïve 
adults, found a prevalence of 9.1% subjects coinfected with HIV and HBV (83). In a study 
conducted in Zambia and Mozambique, among 1032 HIV infected patients, showed 7.6% 
individuals HBsAg positive (36). A study conducted in 2 urban clinics in Zambia and 4 rural 
clinics in Mozambique, 1812 individuals, HIV-positive were enrolled (755 from Zambia and 
1057 from Mozambique), no patient from Mozambique was confirmed Anti-HCV (84).  
A study conducted on 428 Mozambican refugees in South Africa for markers of 
exposure of HBV and HCV, showed that 56% of the population had anti-HBsAg, while 13.2% 
were also HBeAg positive and 3.2% were anti-HCV positive (37). Another study conducted in 
the Malindza camp of refugees, in Swaziland, found the prevalence of 10.8% of HIV, 65.7% 
for any HBV mark and nil HCV (85).  
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A total of 1380 youths, aged 18 -24 years, were enrolled, at Youth Clinic in Maputo 
Central Hospital, to determine the prevalence and incidence of HIV, prevalence of HBV and 
prevalence of Syphilis, and the results of the study showed a prevalence of HIV and HBV of 
5.1% and 12.2%, respectively (86). 
 
Discussion 
There are few studies conducted and published in Mozambique reporting the co-
infection of HIV, HBV, and HCV. One published study was conducted among replacement 
blood donors, in Maputo Central Hospital, found a higher prevalence of HBV with an estimated 
prevalence of 9.3% for HBsAg and lower the prevalence of Anti-HCV (35).  This data is 
consistent with other studies conducted in African countries such as Cameroon where it was 
reported a prevalence of 23.7% in people infected with HIV were HBsAg+, amongst those  
patients 12% also tested positive for HBeAg, which indicates that viral replication was active, 
and 7.2% were Anti-HCV+, and the coinfected prevalence for both HBV and HCV was 2% 
(87), indicating that the risk of HCV infection remains very low in Sub-Saharan countries. 
In a study conducted in Abuja, Nigeria was shown a prevalence of 0.7% in HIV-infected 
people, with HBV and HCV (88). These findings can be explained by the wide variation in the 
way of transmission of these viruses, depending on regions such as Europe, Asia, Central and 
South America, where most transmissions occurs through injectable drug use (89), therefore, 
the studies conducted in Sub-Saharan countries found a similar prevalence of 1.2% of Anti-
HCV positive (90) Due to the shared mode of transmission of both viruses (HBV and HIV) 
coinfection is also common in people infected with HIV in African countries (91).  
The HCV coinfection in HIV-infected people is poorly documented in Mozambique, only 
one study assessed the prevalence of Anti-HCV, among youth at Central Hospital (86). 
Although it is known that with HIV+ people, the chance of HCV infection is higher, but evidence 
from African studies indicate a prevalence of 0.76% for HIV/HCV (91), from the systematic 
review study conducted in Africa, showed a greater predominance of HIV/HBV coinfection 
compared to HIV/HCV coinfection (92). 
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Finally, in Sub-Saharan Africa, where is the heart of HIV pandemic, there is a 
preponderance of HIV and HBV coinfection compared to HIV and HCV, leading to a significant 
limitation of HCV seroprevalence surveys published in the region (92).  
 
Conclusion 
The prevalence of HIV and HBV is higher and, HCV remained of low prevalence in 
Mozambique. HBV may also have been transmitted horizontally in children, and screening for 
HBsAg could contribute substantially to avert the negative impact on morbidity and mortality 
of HIV/HBV coinfected individuals. However, significant investment is required in large multi-
center collaborative prospective clinical cohorts with HIV, HBV and HCV co-infection that 
incorporate sample collection for basic science research, not yet possible in Mozambique.  
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Table 1: Summary of Studies That Highlight the coinfection conducted in Mozambique 
Authors 
(ref. #) 
Group 
Sample 
Size 
Study 
Site 
HIV 
Preval
ence 
Preval
ence of 
HBsAg
-
positiv
e 
Anti-
HCV 
Preval
ence 
Co-
Infectio
n HIV 
and 
HBV 
Preval
ence 
Co-
Infectio
n HIV 
and 
HCV 
Preval
ence 
Most 
freque
nt 
HBV 
Genot
ype 
CD4 T 
Cells count 
HBs
Ag+ 
HBV 
DNA 
HBV-
DNA≥20.00
0 
HBV-
DNA20<20.0
00 
Cunha L 
(31) 
Replece
ment 
Blood 
donors 
1578 
Maputo 
Central 
Hospital 
Men - 
12,3%  
Wome
n - 
15,4% 
Men - 
10.6% 
Wome
n - 
4.5% 
Men - 
1.2% 
Wome
n - 
1.0% 
2.0% - 
A - 
83% 
- - - - 
Stokx J 
(32) 
Blood 
donors 
750 
Provinci
al 
Hospital 
of Tete 
8.5% 10.6% 0.0% 1.0% 0.0% - -   - - 
Dazza MC 
(33) 
Patients 
with 
HCC 
and 
Blood 
donors 
178 
patients 
with 
HCC 
and 194 
blood 
donors 
Maputo 
Central 
Hospital 
- 
66,3% 
patient
s with 
HCC 
and 
13,9% 
Blood 
donors 
4,3% 
patient
s with 
HCC 
and 
3,8% 
Blood 
donors 
- - - - - - - 
Gudo ES 
(34) 
Blood 
donors 
2019 
Maputo 
Central 
Hospital 
Blood 
Bank 
5.7% 6.0% - - - - - - - - 
Wandeler 
G (23) 
HIV-
infected 
patients 
1032 
Mozam
bique 
and 
Zambia 
- 7.6% - 8.0% - - - 
92.9
% 
49.4% 16.7% 
Chambal 
LM (35) 
HIV 
infected 
patients 
518 
Health 
Centres, 
in 
- - - 9.1% - - 
361 T 
Cells/mm3 
- 26.1% 
52.20% 
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Maputo 
City 
Wandeler 
G (36) 
HIV 
infected 
patients 
1057 
Mozam
bique 
and 
Zambia 
- - 0% - - - 
255 
Cells/mm3 
- 77 (49.4%) 26 (16.7%) 
Viegas EO 
(39) 
Youths 1380 
Youth 
clinic in 
Maputo 
Central 
Hospital 
5.1% 12.2% - 4.9% - - 
608 
cells/mm3 
- - - 
42 
 
5.2 Prevalence of HIV, Hepatitis B, Hepatitis C and Syphilis among Pregnant Women in 
Mozambique – a cross-sectional study (paper II).  
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Abstract 
Of the 36.9 million people living with HIV worldwide, it is estimated that some 2 to 4 million 
also have Hepatitis B Virus (HBV) and 4 to 5 million have Hepatitis C virus (HCV) infections. 
Due to shared modes of transmission, HBV, HCV and Syphilis are also major public health 
concerns. The present work aimed at estimating the prevalence of these infections among 
pregnant women attending antenatal care in Nampula, north of Mozambique. This cross-
sectional study was conducted in six urban health facilities offering antenatal care. One in 
every three pregnant women attending their first antenatal appointment were invited to 
participate. Overall 1216 pregnant women accepted to participate of whom approximately half 
provided plasma samples for HIV, Hepatitis B, Hepatitis C and Syphilis tests. Infections were 
assessed according to standard laboratory procedures and algorithms. Behavioral and socio-
demographic data were collected using a structured questionnaire. The prevalence of HIV 
infection was 30.3%, 40 women (6.2%) had chronic Hepatitis B and 451 (69.9%) had had a 
previous Hepatitis B infection, 4 (0.9%) had Hepatitis C and 3 (0.5%) had Syphilis. Among the 
201 HIV-positive women, 29 (14.4%) were aware of their infection and 17 (58.6%) were under 
treatment. Compared to women newly diagnosed with HIV, those aware of their infection were 
older, had a higher gestational age at first appointment, were less frequently primigesta 
although one-third of newly diagnosed women had 4 or more gestations. There were no 
significant differences between the two groups regarding condom use in the last sexual 
intercourse. The prevalence of HIV and hepatitis B among pregnant women in the north of 
Mozambique was very high, syphilis being unexpectedly low. Awareness of HIV status was 
very low and risk behaviors common, reinforcing the central role of prenatal care. 
 
Key Words: Prevalence HIV, HBV, HCV, Syphilis; Coinfections; Pregnant Women  
44 
 
Background  
In 2016, estimates showed that 36.7 million people were living with HIV and AIDS worldwide 
(1). In Sub-Saharan Africa, there are 24 million people living with HIV, adolescent girls and 
young women account for one in four new HIV infection (2). Worldwide, Mozambique is one of 
the most affected countries of HIV and AIDS, with a prevalence, in the general population, of 
11.5% at the ages of 15-49 years old (3). A National Antenatal Care HIV Surveillance Survey, 
conducted by the National Institute of Health, in 2011, showed a national prevalence of 15.4%, 
and 10% in the northern region. In Nampula city, the prevalence was 19.9% (4).  
Globally, of the 35 million people living with HIV, some 2 to 4 million also have Hepatitis B 
Virus (HBV) infection and 4 to 5 million people Hepatitis C virus (HCV) infection (2). HBV is a 
major public health concern with 350 million people chronically infected (5, 6), and in Africa, 
around 75% of hepatocellular carcinoma cases in men is associated with HBV infection (7). 
The World Health Organization (WHO) estimates that the prevalence of HCV worldwide is 
between 1% and 8% in pregnant women, between 0.05% and 5% in children and 
approximately 3% of the world population have been infected (8). The HCV prevalence is 
poorly documented in Mozambique. A study conducted in the city of Maputo showed a 
prevalence of 1% of anti-HCV among replacement blood donors (9); another study conducted 
in Tete province, found a prevalence of 10.6%, where 90% of participants were men (10). 
A study conducted among HIV infected pregnant women in Europe, showed a prevalence of 
4.9% Hepatitis B surface Antigen (HBsAg) positive, 12.3% Anti-HCV positive, and women with 
a history of injecting drugs were those who had the highest Anti-HCV positive while, HBsAg 
positive was associated with African origin (11).  HIV/HBV coinfection is associated with worse 
liver health than HBV mono-infection (7). Another study conducted in Kwazulu-Natal, involving 
570 pregnant women, showed an antenatal HIV and HBsAg prevalence of 41.6% and 5.3%, 
respectively, a 3.1% prevalence of HIV/HBV coinfection, with hepatitis B e Antigen (HBeAg) 
positive and HBV DNA significantly higher in co-infected pregnant women (12). 
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Results from a retrospective study, in Abidjan, showed a similar proportion of HBsAg among 
pregnant women HIV positive and HIV negative, nevertheless chronic HBV, based on DNA 
positive results were more frequent in HIV positive pregnant women, while in HCV prevalence 
for both groups were 1%, and frequency of HIV/HBV coinfection was higher (13). Mother to 
child transmission (MTCT) of HBV is an important mode of transmission because the earlier 
an individual is infected, the more likely he/she will develop a chronic infection (14). Prevention 
of MTCT of HBV continues to be a challenge in most Sub-Saharan African (SSA) countries. 
Despite the HBV birth-dose vaccination implemented, the HBV vaccine coverage remains low 
in most SSA countries (15).  
Routine antenatal HBV screening should be offered, in HIV/HBV endemic regions, especially 
for HIV-positive pregnant women, allowing identification of neonates who are in need of HBV-
passive immunoprophylaxis at birth. This strategy together with antenatal antiretrovirals will 
contribute to reducing the risk of perinatal HBV transmission (12). To reduce the risk of 
infection of mothers, appropriate emphasis should be given to increasing awareness and 
intensive public health education explaining the horizontal transmission HBV (16, 17).  
A study conducted in southern Tanzania showed that HCV in African countries MTCT does 
not play a significant role in HCV infant acquisition (18). 
Syphilis is a major public health problem in Sub-Saharan Africa. A study conducted among 
pregnant women, in Gondar, Ethiopia, found a high prevalence of syphilis (3.7%) and 
coinfection rate of HIV/Syphilis was 1%, the high prevalence of syphilis being among 
housewives (15.2%) and also was associated with illiteracy of husband (19).  
Several studies have shown the relation of adverse pregnancy outcomes with a high 
prevalence of syphilis such as the maternal history of syphilis, congenital syphilis, stillbirth, 
miscarriage among pregnant women (20-22).  The prevalence of syphilis, HIV, and HBV has 
been shown to vary by time period, geographic area and study population (20, 23, 24). 
Routine HIV testing, HBV and syphilis screening at antenatal care represent an opportunity to 
adopt preventive behaviors on prevention and transmission strategies of these diseases, and 
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this could emphasize individual and societal benefits when pregnant women are aware of her 
condition (22, 25, 26).  
The objective of the present study was to assess the prevalence of HIV, HBV and HCV 
coinfections among HIV patients and pregnant women in Nampula, Mozambique. 
Methods 
Setting and study population 
This was a cross-sectional study conducted from February 2013 to January 2014 in six 
urban health facilities offering antenatal care services in Nampula City, Mozambique. The 
health facilities were in five health centres (“Hospital Geral de Marrere”, “Centro de Saúde 25 
de Setembro”, “Centro de Saúde 1º de Maio”, “Centro de Saúde de Namicopo”, “Centro de 
Saúde 1º de Maio” and “Centro de Saúde de Muhala Expansão”). One in every three pregnant 
women attending the six health centers for their first prenatal appointment were invited to 
participate in the study. In total, 1440 pregnant women were invited to participate and 1216 
(84.4%) agreed to participate. Participation in the study involved a face-to-face interview 
conducted by trained maternal and child health nurses and the collection of blood for laboratory 
analysis of HIV infection, Hepatitis B and Hepatitis C and syphilis. 
Ethics 
The study was approved by the Ministry of Health and by the National Bioethics 
Committee of Mozambique. All measures were taken to ensure confidentiality and not to 
change the normal service procedures. The interviews were conducted in a consultation office, 
where pregnant women followed all the clinically recommended procedures. All participants 
gave their written informed consent prior to inclusion.  
Questionnaire and measurement tools 
Maternal and child health nurses were trained to conduct the face-to-face interviews 
using a structured questionnaire. The structured questionnaires included sociodemographic 
information (age, sex, marital status, occupation, education); use of alcohol, tobacco, drugs 
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and non-prescribed pills; information on maternal health (weight, gestational age, parity and 
history of abortion); information on sexual health (age at 1st sexual intercourse, type of partner 
and condom use in the last sexual intercourse, other sexual partners); history of non-sexual 
exposures to HIV, HBV, HCV; knowledge regarding HIV/AIDS, HBV, HCV modes of 
transmission and knowledge regarding other sexually transmitted infections (STI´s); history of 
HIV, hepatitis B, hepatitis C, STI and tuberculosis diagnosis.  
Data were entered into a database and double checked for accuracy.  
Blood samples were collected as part of the routine procedures of the first antenatal 
care appointment established by the National Health Services (NHS) that include the test for 
HIV infection and syphilis. The analysis for Hepatitis B and Hepatitis C were added as part of 
this study. The tests were performed at the laboratory of National Institute of Health, at the 
Ministry of Health.  
During transportation from Nampula to Maputo, a considerable amount of plasma 
samples out of the 1216 collected from pregnant women were lost by the national air carrier. 
In the end, 663 (54.5%), 645 (53.0%), 435 (35.8%) and 666 (54.8%) plasma samples were 
available for laboratory analysis of HIV, Hepatitis B, Hepatitis C and Syphilis, respectively.  
Laboratory procedures  
Plasma samples of pregnant women were collected and kept frozen at −80°C until 
analysis. Participants were informed, in following appointments, about the analytical results. 
For those who were positive, either for HIV positive or Syphilis positive results, were treated 
following the available and recommended specifics medicines. 
Screening for HIV 
Screening for HIV was performed using Vironostika HIV Ag/Ab (Biomerieux SA, Marcy 
l' Etoile, France), a 4th generation enzyme immunoassay to detect HIV-1/2 antibodies and 
HIV-1 p24 antigen (manufacturer-described Sensitivity of 100% and Specificity of 99.5%). The 
non-reactive results were considered as negative for HIV and the reactive results were further 
confirmed using MP Diagnostics HIV Ag/Ab Combo ELISA 4.0 (MP Biomedicals Asia Pacific 
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Pte Ltd, Singapore), an enzyme-linked immunosorbent assay (ELISA) to detect HIV-1 (group 
M - O) or 2 antibodies and/or antigens (manufacturer-described Sensitivity of 100% and 
Specificity of 99.76%). A reactive result on this second test confirmed the HIV infection and 
was considered positive. Those having a non-reactive result in the second test were retested 
using the same assay. If the result was reactive, the samples were classified as being positive 
for HIV, and if the result was non-reactive, the samples were classified as negative for HIV. 
There were a few samples that were classified as having indeterminate results either due to 
discordant results in the two assays or insufficient plasma to complete the testing procedures.  
Screening of biomarkers for HBV 
All plasma samples were tested for Hepatitis B Virus Surface Antigen (HBsAg) using 
an ELISA test MP Diagnostics HBsAg ELISA 4.0 (MP Biomedicals Asia Pacific Pte Ltd, 
Singapore; manufacturer-described Sensitivity of 100% and Specificity of 99.58%), for 
antibodies to Hepatitis B Virus Surface Antigen (anti-HBs) using the MP Diagnostic Anti-HBs 
ELISA 4.0 (MP Biomedicals Asia Pacific Pte, Ltd, Singapore; manufacturer-described 
Sensitivity of 100% and Specificity of 99.58%), for Hepatitis B Virus e Antigen (HBeAg) using 
the  4.0 MP Diagnostic HBeAg ELISA (MP Biomedicals Asia Pacific Pte Ltd, Singapore; 
manufacturer-described Sensitivity of 100% and Specificity of 99.93%) and, finally, for 
antibodies to Hepatitis B Virus Core Antigen (anti-HBc) using the MP Diagnostics Anti-HBc 
ELISA 4.0 (MP Biomedicals Asia Pacific PTE Ltd, Singapore; manufacturer-described 
Sensitivity of 99.82% and Specificity of 99.92%) and finally. The Hepatitis B status was then 
coded into the following categories according to the results of the previous tests: no previous 
contact (anti-HBc negative); previous infection resolved (anti-HBc positive and HBsAg 
negative); and chronic infection (anti-HBc positive and HBsAg positive) 
Screening for HCV 
Screening for HCV was performed by the detection of antibodies to the HCV (anti-HCV) 
using the HCV ELISA 3.0 MP Diagnostic (MP Biomedicals Asia Pacific Pte, Ltd, Singapore; 
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manufacturer-described Sensitivity of 99.79% and Specificity of 99.55%). The presence of anti-
HCV antibodies in plasma samples was indicative of infection by hepatitis C. 
Screening for Syphilis 
The assessment of syphilis infection was performed using first a non-treponemal test - 
the Rapid Plasma Reagin (RPR) intended to detect antibodies to non-treponema antigen 
directed against a lipoid structure (phospholipids), resulting from T. pallidum infection. If the 
qualitative result of the test was non-reactive the sample was considered negative for syphilis. 
All samples with a reactive qualitative RPR result were diluted in 1:2, 1:4, 1:8, 1:16 and 1:32 
dilutions and a confirmatory treponemal test were performed – the T. pallidum particle 
agglutination test (TPPA).  
Statistical Analysis 
The characteristics of participants were described using absolute and relative 
frequencies in the case of categorical variables. Means and standard deviation (SD) were used 
to describe continuous variables. Comparisons between groups were performed using the χ2 
test or Fisher’s exact test when variables were categorical. For continuous variables, the T-
student test for independent samples was used.  A significance level was fixed at 0.05. The 
analyses were performed using the SPSS software for Windows, version 22.0 (SPSS Inc., 
Chicago, Illinois, USA). 
Results 
The age of the participants was 22 (18-28) years. The majority of participants 498 
(41.5%) were cohabiting with a partner. Most women 449 (39.6%) either did not finish primary 
school or had no education, and the majority 929 (77.3%) were housewives. Most women 669 
(56.2%) had their first sexual intercourse at age range 15-17 years. 
It was found a prevalence of HIV infection of 30.3% (202 women), of these HIV-positive 
women 29 (14.4%) were aware of the infection and 17 (8.4%) were under treatment. Forty 
women (6.2%) had chronic Hepatitis B and 451 (69.9%) had had a previous Hepatitis B 
infection, of these only 3 reported a previous diagnosis of Hepatitis B. The prevalence of 
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Hepatitis C was of 4 (0.9%) women, of these none, reported to be aware of the infection. Three 
women (0.5%) had an active syphilis of whom 2 reported a previous diagnosis of syphilis.  
In this study, it was found a prevalence of coinfection HIV/HBV, HIV/HCV, and 
HIV/Syphilis, of 3.6%, 0.2% and 0.5%, respectively.  
The prevalence of HBV (HBs Antigen) in HIV infected pregnant women was higher 30 
(9.8%) compared to HBV 45 (6.8%) pregnant women HIV negative, however, the difference 
was not statistically significant (p=0.1). 
Compared to women newly diagnosed with HIV, those aware of their infection were 
older (mean age 26.5 vs 23.0 old) and were less frequently married or cohabiting with a partner 
(17.2% and 24.1% vs 21.3% and 39.6%, respectively). No other differences were found in 
sociodemographic characteristics such as education and job situation. Concerning the 
maternal health women that were aware of their infection had a higher gestational age at first 
appointment (61.5% at 28 weeks or more vs 36.4%), were less frequently primigesta (7.4% vs 
27.1%) although one-third of newly diagnosed women had already 4 or more gestations. There 
were no differences between the two groups regarding age at sexual debut, condom use in 
the last sexual intercourse and having had other partners beyond last sexual partner in the 
previous 6 months and women that were aware of their HIV infection reported more frequently 
that their last sexual partner was a friend or occasional partner that women that were newly 
diagnosed (20.7% vs 3.7%).  
Discussion 
The purpose of this study was to determine the prevalence of coinfection among 
pregnant women attending antenatal care, in Nampula city. The prevalence of 30.3% found in 
the present study is higher than that found by the National Antenatal care HIV Surveillance 
survey of 2011 for the health center located in the city of Nampula (19.9%) (4). The difference 
may be due to a larger sample (867) representative of the different degrees of risk since it was 
collected in all health centers of Nampula City while in the National Antenatal care HIV 
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Surveillance Survey the sample was smaller (357) from only one health center covering a 
smaller geographic area. 
Little is known about the status of HIV co-infection with HBV, HCV, and syphilis in this 
population community so that these coinfected people may benefit from ART, including the 
treatment of associated coinfections (27). Pregnant women are an important group to be 
addressed, for designing interventions intending to reduce the burden of these diseases in the 
communities (28, 29). 
The present study demonstrated that there were non-significant differences in HBV 
prevalence between HIV-infected and uninfected pregnant women. This finding is similar to 
other reported Southern Africa (SA) studies that may be explained by the cryptic transmission 
of childhood HBV instead of the shared routes of transmission of HIV and HBV in adulthood 
(30). 
With regard to coinfection with HIV/HBV in pregnant women, it does not increase the 
risk of HIV transmission (31), however it is crucial to study the coinfection among pregnant 
women, because these women form a significant reservoir for horizontal or perinatal 
transmission of HBV and the establishment of routine screening to such women could allow 
an identification of a new baby born that require an active or passive immunoprophylaxis at 
birth. This may reduce the risk of HBV perinatal transmission in coinfected women that are 
considered to be of high risk (12). A history of induced abortion, baseline ALT elevated are 
significantly associated with HBV infection (28). 
In Africa, 40% to 60% of people who are chronic carriers of HBV, have acquired an 
infection during pregnancy (32). The World Health Organization recommends that, in countries 
with high HIV and HBV prevalence, pregnant women must be screened for HBV in order to 
start treatment recommended in the first quarter of pregnancy (33). The present study found 
HIV/HBV coinfection in 3.6% of pregnant women. These results are consistent with studies in 
other African countries, such as Republic of South Africa: HIV/HBV coinfection prevalence of 
3.1% in Kwazulu Natal (12), and Angola: of 2.3% in Luanda (34). 
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In this study, it was found a prevalence of 0.9% Anti-HCV and the coinfection with 
HIV/HCV was 1 (0.2%). It is known that in HIV-positive people, the chance of HCV infection is 
higher, nevertheless, the evidence from African studies indicated a prevalence of 0.76% for 
HIV/HCV (35). 
The prevalence of syphilis in this study was relatively low at 0.5%. This finding is 
consistent with studies conducted in other African countries, where the prevalence of syphilis 
in pregnant women was lower than that for most other prevalent sexually transmitted diseases, 
such as HIV and HBV (24, 36, 37). In one of these studies, syphilis was associated with 
reporting more than one lifetime sexual partner (36). 
In this study, it was found that the prevalence of HIV/HBsAg+, HIV/anti-HCV, and 
HIV/syphilis, were 3.6%, 0.2% and 0.5%, respectively. These data are consistent with other 
African studies that have revealed a common frequency and prevalence of these infections 
(37-39).  Coinfection with HIV/HBV was the most frequent and it was present in 3.6% of 
pregnant women, followed by HIV/syphilis and HIV/HCV which was found lowest in pregnant 
women. In African countries coinfection with HBV, HCV and Syphilis with HIV are most 
common among pregnant women (28, 29, 37). A systematic review study conducted in Sub-
Saharan Africa showed a greater predominance of HIV/HBV coinfection compared to HIV/HCV 
coinfection (40). 
The present study did not find the simultaneous coinfection by the three viruses. In a 
study conducted in Abuja, Nigeria, it was observed a prevalence of 0.7% in HIV-infected 
people, with HBV and HCV (41). These findings can be explained by the wide variation in the 
way of transmission of these viruses, depending on regions such as Europe, Asia, Central and 
South America, where most transmissions occurs through injectable drug use (42). Therefore, 
this prevalence should be compared with studies conducted in other countries in Sub-Saharan 
Africa where it was found a similar prevalence of 1.2% of Anti-HCV positive (43). 
This study found an HIV/HCV coinfection prevalence of 0.2%. Similar studies in 
Tanzania and Angola have shown that MTCT does not play a significant role in HCV 
transmission (18, 34). The coinfection HIV/HCV, although not being a public health problem in 
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Mozambique, it is known that factors such as the Maternal HIV coinfection, HCV maternal viral 
load, intrapartum invasive procedures play a great roll on HCV maternal transmission (44, 45). 
In other studies conducted in African countries, the prevalence of HIV/HCV coinfections was 
2.38% (46), which is in agreement with those observed in the present study. 
Comprehensive screening for all pregnant women, as part of prevention strategies, 
needs to be reinforced (24, 37). A Nigerian study of sexual behavior in pregnant women 
revealed a decrease of sexual desire and frequency during pregnancy, and the majority of 
women (60%) started to use condoms after an HIV diagnosis in pregnancy to decrease the 
transmission of the virus (47). Prevention programs could increase the awareness of the risk 
of infection with HIV and other sexually transmitted diseases, by increasing condom use, 
women may also prevent future pregnancy (48). 
Conclusion  
The prevalence of HIV and hepatitis B among pregnant women in the north of 
Mozambique was found to be very high, syphilis being unexpectedly low. Awareness of HIV 
status was very low and risk behaviors common, reinforcing the central role of prenatal care. 
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Table 1. Comparison of pregnant women HIV-positive according to being aware of their HIV 
status. 
  
Pregnant women HIV-
positive 
 
 Unaware Aware  p-value 
 173 (85.6%) 29 (14.4%)  
SOCIODEMOGRAPHIC CHARACTERISTICS    
Health center   0.240* 
Centro de Saúde Muhala Expansão 59 (35.8) 16 (55.2)  
Hospital Geral de Marere 5 (3.0) 0 (0.0)  
Centro de Saúde 25 de Setembro 56 (33.9) 7 (24.1)  
Centro de Saúde 1º Maio 34 (20.6) 3 (10.3)  
Other 11 (6.7) 3 (10.3)  
Total 165 29  
Age strata, years   0.012 
<18 32 (20.3) 1 (3.6)  
18-19 34 (21.5) 1 (3.6)  
20-24 32 (20.3) 8 (28.6)  
25-29 31 (19.6) 10 (35.7)  
≥30 29 (18.4) 8 (28.6)  
Total 158 28  
Marital Status   0.030 
Single/Widow/ Divorced /separated 12 (7.3) 7 (24.1)  
Married  34 (20.7) 5 (17.2)  
Cohabiting with partner 65 (39.6) 7 (24.1)  
Married traditionally  53 (32.3) 10 (34.5)  
Total 164 29  
Education   0.105 
Without education  29 (17.7) 11 (37.9)  
Did not finish primary school  32 (19.5) 5 (17.2)  
Primary school (1st degree) 21 (12.8) 1 (3.4)  
Primary school (2nd degree) 34 (20.7) 5 (17.2)  
Secondary School 39 (23.8) 4 (13.8)  
Pre-University/University 9 (5.5) 3 (10.3)  
Total 164 29  
Job situation   0.121* 
Employed 3 (1.8) 2 (6.9)  
Student 24 (14.6) 2 (6.9)  
Housewife/Unemployed 126 (76.8) 25 (86.2)  
Agriculture/Farmer 11 (6.7) 0 (0.0)  
Total 164 29  
MATERNAL HEALTH    
Gestational age at first appointment, classes   0.045 
14 weeks or less 12 (7.3) 2 (7.7)  
15-27 weeks 93 (56.4) 8 (30.8)  
28 weeks or more 60 (36.4) 16 (61.5)  
Total 165 26  
Number of gestation   0.047 
1 45 (27.1) 2 (7.4)  
2 40 (24.1) 5 (18.5)  
3 24 (14.5) 4 (14.8)  
≥4 57 (34.3) 16 (59.3)  
Total 166 27  
History of abortion    0.129 
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No 135 (81.3) 19 (67.9)  
Yes 31 (18.7) 9 (32.1)  
Total 166 28  
SEXUAL HEALTH    
Age at sexual debut, years   0.642* 
<15 22 (13.3) 2 (6.9)  
15-17 94 (57.0) 16 (55.2)  
18-19 4 (2.4) 0 (0.0)  
≥20 2 (1.2) 0 (0.0)  
Does not remember 43 (26.1) 11 (37.9)  
Total 165 29  
Condom use in the previous sexual intercourse   >0.999* 
No/Never heard about condoms 156 (94.5) 28 (96.6)  
Yes 9 (5.5) 1 (3.4)  
Total 165 29  
Last sexual partner   0.004* 
Husband 149 (92.0) 21 (72.4)  
Boyfriend 6 (3.7) 1 (3.4)  
Friend/Occasional partner 6 (3.7) 6 (20.7)  
Rather not answer 1 (0.6) 1 (3.4)  
Total 162 29  
Other partners beyond last sexual partner in the 
previous 6 months 
  0.302* 
No 134 (82.7) 21 (75.0)  
Yes 26 (16.0) 6 (21.4)  
Rather not answer 2 (1.2) 1 (3.6)  
* Fisher exact test 
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ABSTRACT
The assessment of pregnant women’s knowledge about modes of infections transmission is
essential to tailor programs to their needs. This study aimed to assess knowledge about human
immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV) among
pregnant women in Nampula – Mozambique, a high-risk area for sexually transmitted infections.
At their first antenatal visit, women were invited to participate and data were collected by
trained nurses at six public health facilities. Knowledge about HIV transmission modes was high
but relevant misconceptions remained. However, knowledge regarding HBV and HCV
transmission modes was very limited. There was a significant association between knowledge
level and socioeconomic position, making education and women’s empowerment key factors in
a comprehensive strategy to prevent infections.
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Introduction
Mozambique is one of the most affected countries by the
human immunodeficiency virus (HIV) epidemic with an
estimated prevalence, in 2009, of 11.5% among 15–49 age
group. Women in the age group of 15–24 had an esti-
mated prevalence of 11.1%, much higher than the 3.7%
prevalence amongmen in the same ages (Instituto Nacio-
nal de Saúde (INS), Instituto Nacional de Estatística
(INE), & ICF Macro. 2010, 2010). Increased knowledge
regarding HIV prevention among mothers was associ-
ated with less HIV infection in their children (Brewer,
2012) and is one of the core indicators to measure pro-
gress in the response to the epidemic (UNAIDS, 2014).
Similarly to HIV, Hepatitis B virus (HBV) and Hepa-
titis C virus (HCV) are endemic in Mozambique and
share transmission modes. A previous study showed a
prevalence of 10.6% and 4.5% for HBV surface antigen
(HBsAg) and of 1.2% and 1.0% for anti-HCV respect-
ively among men and women blood donors in Maputo
(Cunha et al., 2007).
Therefore, as for HIV, increased knowledge about
transmission of viral hepatitis is important to prevent
these infections (Chan, Lao, Suen, Lau, & Leung, 2011;
Dinh et al., 2015; Tegegne, Desta, Tegbaru, & Tilahun,
2014). Pregnancy may be a privileged opportunity to
educate women as those with at least one prenatal visit
have been increasing, reaching 91% in 2012 (Ministério
da Saúde, 2012) and they may be more predisposed to
accept education about prevention (Ashimi, Omole-
Ohonsi, Amole, & Ugwa, 2014; Barth, Huijgen, Taljaard,
& Hoepelman, 2010). This study aimed to assess knowl-
edge regarding HIV, HBV, and HCV among pregnant
women in Nampula, Mozambique. Monitoring pregnant
women’s knowledge in a setting highly affected by these
infections will provide information to tailor education
programs.
Methods
A cross-sectional study was conducted in six urban
health units in Nampula, Mozambique, offering ante-
natal care services. Nampula is located in northern
Mozambique and the second most populated city in
the country. Data was collected from February 2013 to
January 2014 during face-to-face interviews conducted
by trained maternal and child health nurses. An esti-
mated average of 60 first prenatal appointments were
expected per day. One in every three pregnant women
attending their first prenatal appointment was invited
to participate in the study. This strategy was considered
to provide the best balance between causing the minimal
disturbances to the daily work and time and resources
available at the healthcare units. Overall, 1440 women
were invited and 1216 (84.4%) agreed to participate. Of
© 2018 Informa UK Limited, trading as Taylor & Francis Group
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those, 1186 women provided a valid answer to the vari-
ables of interest.
A structured questionnaire was used to collect data on
sociodemographic, behaviors, reproductive health, sex-
ual history, previous diagnosis of infectious diseases, his-
tory of non-sexual exposures to HIV, HBV and HCV.
The questions to test knowledge about transmission
modes were based on a national survey on HIV preva-
lence in Mozambique (Instituto Nacional de Saúde
(INS) et al., 2010) for a direct comparison.
Latent Class Models (LCM) were used to identify
classes of knowledge about HIV, HBV and HCV trans-
mission modes. LCM with three classes showed the
smallest Bayesian information criterion and the smallest
Akaike’s Information Criterion (data not shown).
The model was interpreted by looking at the probabil-
ities of correct answers on each item, conditional on class
membership. For HIV, the first class presented the high-
est mean proportion of correct answers (83.9%) and the
highest probability of correct answers for the false items;
the second class presented the highest probabilities of the
correct answer for the true items and a mean proportion
of correct answers of 68.0%; the third class showed the
lowest probability of a correct answer for almost all the
items (mean of 23.7%). For HBV, the first class showed
the highest mean proportion of correct answers
(71.7%) and the highest probability of correct answers
for almost all the items; the second class presented the
highest probability of a correct answer for item 7 and a
mean proportion of correct answers of 32.4%; the third
class showed the lowest probability of a correct answer
for almost all the items (mean of 0.2%). For HCV, the
first class presented the highest mean proportion of cor-
rect answers (75.4%) and the highest probability of cor-
rect answers for almost all the items; the second class
presented the highest probability of a correct answer
for the items 5, 6 and 7 (all false) and a mean proportion
of correct answers of 41.6%; the third class showed the
lowest probability of a correct answer for almost all the
items (mean of 0.1%). The proportions of correct
answers for each type of infection are presented in
Table 1.
Comparisons of proportions by latent classes were per-
formed using the chi-square test (Pearson or Fisher’s
exact test) or McNemar as appropriate. A significance
level was fixed at 0.05. Analysis were performed using
the SPSS software for Windows, version 22.0 (SPSS Inc.,
Chicago, Illinois, USA). LCM were performed using the
software R 2.8.1, specifically the poLCA package.
The study was approved by the Ministry of Health
and by the National Bioethics Committee of Mozambi-
que. Written informed consent was obtained from all
participants.The interviews were conducted by nurses Ta
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in a consultation office to ensure privacy and all
measures were taken to ensure confidentiality.
Results
The median age of the 1186 participants included was 22
years (Interquartile range = 10), 39.4% women had no
formal education or did not finish primary school, and
most were housewives (77.9%). The majority of women
were cohabiting with a partner (41.1%) and 56.0% had
their first sexual intercourse between 15 and 17 years
of age. The self-reported prevalence of HIV, HBV and
HCV was 6.4%, 0.3% and 0.1%, respectively (Table 2).
Significant differences in sociodemographics, sexual
history, and reproductive health characteristics were
found regarding knowledge about HIV, HBV and
HCV transmission modes. Women in class 1, those
with the highest probability of correct answers, had
higher levels of education, reported more frequently to
be employed or student, had their first sexual inter-
course at the age of 15–17, and reported more fre-
quently to have used a condom in their last sexual
intercourse. Women’s age was not significantly associ-
ated with HIV and HBV knowledge, but, younger
women were more often represented in class 1 of
HCV knowledge. Women that attend the first antenatal
visit earlier in pregnancy were significantly more rep-
resented in class 1 for HBV and women that presented
later in class 3 for HCV (Table 2).
To have heard about HIV/AIDS, Syphilis, Gonor-
rhoea, Tuberculosis, Hepatitis B or Hepatitis C, was
associated with better knowledge about HIV trans-
mission modes. However, only those who have heard
about Hepatitis B or Hepatitis C were more represented
in class 1 of knowledge about HBV and HCV. Self-
reported diagnosis of syphilis, gonorrhoea and tubercu-
losis were associated with more knowledge of HIV
transmission modes. In general, reporting a history of
non-sexual risk namely blood transfusion, tattoos and
piercings was associated with poorer knowledge about
transmission modes (Table 2).
Table 3 shows that agreement between knowledge
about HBV and HCV transmission modes was very
good (Kappa = 0.731), while the agreement between
knowledge about HIV and each of the hepatitis virus
was poor.
Discussion
Our results showed high levels of knowledge about trans-
mission modes for HIV among pregnant women acces-
sing antenatal care in Nampula, as 60.5% of women
were in class 1 corresponding to the highest mean
proportion of correct answers. However, knowledge of
transmission modes for HBV and HCV was lower with
23.6% and 18.4%, of women in a similar class 1, respect-
ively. A higher knowledge of HIV was expected since
more attention has been paid to this infection, but the
low evidenced knowledge about viral hepatitis is of
major concern.
The results on knowledge about HIV were similar to
previous studies among pregnant women in other Afri-
can countries (Moses, Chama, Udo, & Omotora, 2009;
Ojieabu, Femi-Oyewo, & Eze, 2011). The increased
awareness of HIV transmission modes may be due to
the structured programs of health education related to
HIV implemented in schools and at health facilities
across the country and to the establishment of commu-
nity health education programs by governmental and
non-governmental organizations as response to the
different national strategic plans (Conselho Nacional
de Combate ao SIDA, 2010; Ministério da Saúde,
2004; Conselho Nacional de Combate ao HIV/AIDS,
2004).
Lack of knowledge about HBV was evident in the low
frequency of respondents that had ever heard about
HBV. This is particularly concerning since HBV, a vac-
cine-preventable disease, is for many years endemic in
Mozambique (Cunha et al., 2007; Stokx et al., 2011).
The immunization of children against HBV is already
implemented in Mozambique and could provide an
opportunity to increase knowledge (Ministério da
Saúde, 2001; Viegas et al., 2015). Knowledge about
modes of HCV transmission is meagre which can be par-
tially explained by the lower prevalence of HCV infection
in the country and lower health education on HCV com-
pared to HIV and HBV (Tiruneh, 2008; Yeung et al.,
2014). Also, the fact that the HCV was for long time
associated with intravenous drug use, relatively uncom-
mon in Africa, might partially justified the lack of aware-
ness of this infection.
In our study the self-reported diagnosis of HIV, HBV
and HCV infection might be underreported considering
the estimated prevalence among women in Mozambique
(Cunha et al., 2007; Instituto Nacional de Saúde (INS)
et al., 2010) and the lack of knowledge about HBV and
HCV limited our ability to draw any conclusion on the
impact of diagnosis in the knowledge about transmission
modes.
We must acknowledge that the recruitment strategy
used, excluding women that did not attend antenatal
care services, might have resulted in an oversampling
of those more aware. Women that do not use health ser-
vices, may have particularly lower levels of knowledge as
we might expect them to have the lowest levels of edu-
cation and health awareness.
AIDS CARE 3
Table 2. Comparison of women in each of the 3- classes of knowledge about HIV, HBV and HCV transmission modes according to sociodemographic characteristics, sexual life, maternal
health, previous knowledge of infectious diseases, self-reported infection and history of non-sexual exposures
Total sample
Knowledge about transmission modes
HIV HBV HCV
Class 1 Class 2 Class 3 p-value Class 1 Class 2 Class 3 p-value Class 1 Class 2 Class 3 p-value
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
1186 687 (60.5) 295 (26.0) 154 (13.6) 274 (23.6) 149 (12.8) 738 (63.6) 214 (18.4) 146 (12.6) 801 (69.0)
Sociodemographic Characteristics n (%) % % % % % % % % %
Age (years) 0.200 0.079 0.011
<18 201 (17.4) 19.0 12.9 22.4 20.5 15.9 16.7 20.7 15.4 17.1
18–19 201 (17.4) 16.4 20.7 15.8 21.3 17.2 16.3 24.0 20.3 15.3
20–24 326 (28.2) 28.6 28.6 23.0 25.4 24.1 30.3 19.2 25.2 30.9
25–29 229 (19.8) 19.9 20.0 19.1 16.0 27.6 19.5 17.3 23.1 19.6
≥30 198 (17.1) 16.1 17.9 19.7 16.8 15.2 17.2 18.8 16.1 17.1
Marital status <0.001 <0.001 <0.001
Single/Divorced /separated/ Widow 130 (11.1) 11.5 8.5 10.7 11.7 6.8 11.1 14.0 7.6 10.8
Married 227 (19.4) 21.4 13.9 22.7 18.7 33.3 16.9 15.9 36.1 17.4
Cohabiting with partner 481 (41.1) 37.8 44.9 50.7 42.1 23.1 44.6 40.7 28.5 43.8
Married traditionally 333 (28.4) 29.2 32.7 16.0 27.5 36.7 27.4 29.4 27.8 28.0
Education <0.001 <0.001 <0.001
Without education 243 (20.6) 12.2 27.9 45.5 11.7 12.2 25.7 9.3 18.1 23.9
Did not finish primary school 221 (18.8) 17.1 21.4 22.7 13.5 13.6 22.0 14.5 11.8 21.3
Primary school (1st degree) 142 (12.1) 12.1 9.2 16.9 6.2 19.0 12.8 4.7 17.4 13.2
Primary school (2nd degree) 224 (19.0) 22.2 17.0 7.8 20.8 21.8 17.9 19.2 20.1 18.6
Secondary School 267 (22.7) 27.1 21.4 5.8 35.4 25.9 17.5 38.3 25.7 18.1
Pre-University/University 80 (6.8) 9.4 3.1 1.3 12.4 7.5 4.1 14.0 6.9 4.8
Job situation <0.001 <0.001 <0.001
Employed 48 (4.1) 5.7 1.7 0.0 5.1 5.4 3.1 5.6 4.9 3.5
Student 165 (14.1) 17.8 10.9 4.6 24.3 10.9 10.7 26.6 12.6 10.6
Housewife/Unemployed 914 (77.9) 73.3 82.0 92.7 65.1 81.0 82.6 60.7 80.4 82.5
Agriculture/Farmer 47 (4.0) 3.2 5.4 2.6 5.5 2.7 3.6 7.0 2.1 3.4
Sexual history
Age at 1st sexual intercourse, years <0.001 <0.001 <0.001
<15 148 (12.6) 12.9 13.6 9.8 10.3 10.8 13.9 9.5 11.0 13.6
15–17 660 (56.0) 65.5 46.6 33.3 70.6 61.5 49.4 66.8 65.8 51.3
18–19 24 (2.0) 1.9 2.7 0.7 4.0 2.0 1.2 6.2 1.4 1.1
≥20 36 (3.1) 3.4 3.1 0.7 4.0 6.8 2.0 4.3 4.8 2.5
Does not remember 310 (26.3) 16.4 34.0 55.6 11.0 18.9 33.5 13.3 17.1 31.5
Used condom in the last sexual intercourse 72 (6.1) 7.5 4.7 2.0 0.020 8.4 4.0 5.2 0.093 10.3 4.8 5.3 0.020
Last sexual partner 0.120 0.184 0.185
Husband 1015 (87.3) 85.7 91.0 89.3 86.9 91.3 87.0 84.1 91.7 87.3
Boyfriend 80 (6.9) 8.0 5.2 4.0 8.0 2.7 7.0 10.3 4.8 6.4
Friend/ Occasional partner 53 (4.6) 5.2 3.1 4.0 4.7 5.4 4.2 5.1 2.8 4.6
Rather not answer 15 (1.3) 1.2 0.7 2.7 0.4 0.7 1.8 0.5 0.7 1.7
Other partner besides last sexual partner
in the previous 6 months
0.007a 0.012a 0.131a
No 1006 (87.3) 86.2 87.3 90.7 90.1 80.3 87.5 90.5 83.2 87.4
Yes 136 (11.8) 13.1 12.3 6.0 9.6 19.7 11.1 9.0 16.8 11.4
Rather not answer 11 (1.0) 0.7 0.4 3.3 0.4 0.0 1.4 0.5 0.0 1.3
Reproductive health
Gestational age at first antenatal care visit 0.756 0.010 0.037
14 weeks or less 90 (7.7) 8.1 6.8 7.8 10.1 9.6 6.2 8.1 9.7 6.9
15–27 weeks 648 (55.7) 55.8 53.9 58.8 61.2 51.4 54.4 59.8 62.5 53.5
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28 weeks or more 426 (36.6) 36.2 39.2 33.3 28.7 39.0 39.4 32.1 27.8 39.6
Number of pregnancies 0.077 0.230 0.158
1 336 (28.6) 29.6 26.1 32.0 32.6 29.7 26.8 34.3 26.9 27.9
2 248 (21.1) 20.5 21.7 19.0 24.2 18.9 20.5 24.9 20.7 19.9
3 182 (15.5) 17.6 13.2 9.8 14.3 14.9 15.7 13.1 15.2 16.1
≥4 410 (34.9) 32.3 39.0 39.2 28.9 36.5 36.9 27.7 37.2 36.1
Ever had an abortion 185 (15.7) 17.4 14.9 10.4 0.087 13.2 17.6 16.3 0.394 14.1 15.9 16.2 0.744
Ever heard about:
HIV 1118 (94.6) 96.6 91.5 92.2 0.001 96.0 95.3 94.0 0.438 95.8 95.2 94.1 0.587
Hepatitis B 288 (24.4) 29.5 18.1 9.1 <0.001 48.9 34.9 12.1 <0.001 51.6 36.3 14.0 <0.001
Hepatitis C 225 (19.0) 22.2 15.0 9.1 <0.001 42.5 25.0 8.0 <0.001 47.2 29.7 8.8 <0.001
Syphilis 1050 (88.8) 90.4 88.8 81.8 0.010 89.7 87.9 88.5 0.806 89.3 90.4 88.2 0.718
Gonorrhea 1071 (90.5) 93.4 88.8 82.5 <0.001 93.4 89.9 89.4 0.155 92.5 93.2 89.5 0.205
Tuberculosis 1061 (90.1) 93.1 89.2 79.9 <0.001 91.9 91.9 88.8 0.244 92.0 91.7 89.2 0.364
Self-reported infection
HIV 0.844a 0.667a 0.336a
No 1087 (93.3) 92.8 94.1 94.7 94.5 95.3 92.5 95.8 95.9 92.5
Yes 75 (6.4) 6.8 5.9 5.3 5.5 4.7 7.1 4.2 4.1 7.2
Does not know 3 (0.3) 0.4 0.0 0.0 0.0 0.0 0.4 0.0 0.0 0.4
Hepatitis B 0.599a <0.001a 0.006a
No 1129 (96.9) 97.2 95.5 97.3 97.4 100.0 96.0 97.7 99.3 96.2
Yes 4 (0.3) 0.3 0.7 0.0 1.5 0.0 0.0 0.9 0.7 0.1
Does not know 32 (2.7) 2.5 3.8 2.7 1.1 0.0 4.0 1.4 0.0 3.7
Hepatitis C 0.326a 0.006a 0.008a
No 1125 (96.8) 97.3 95.2 96.7 97.4 100.0 95.8 97.2 99.3 96.1
Yes 1 (0.1) 0.1 0.0 0.0 0.4 0.0 0.0 0.0 0.7 0.0
Does not know 36 (3.1) 2.5 4.8 3.3 2.2 0.0 4.2 2.8 0.0 3.9
Syphilis 0.001a 0.068a 0.368a
No 1114 (95.6) 94.7 96.9 96.7 97.8 93.3 95.3 97.7 95.2 95.3
Yes 44 (3.8) 5.2 2.8 0.7 2.2 4.7 4.2 2.3 3.4 4.1
Does not know 7 (0.6) 0.1 0.3 2.7 0.0 2.0 0.6 0.0 1.4 0.6
Gonorrhea 0.027a 0.039 0.176
No 1127 (97.1) 96.7 98.3 98.0 97.8 93.9 97.5 98.1 94.5 97.3
Yes 25 (2.2) 2.8 1.4 0 2.2 3.4 1.8 1.9 3.4 1.9
Does not know 9 (0.8) 0.4 0.3 2.0 0.0 2.7 0.7 0.0 2.1 0.8
Tuberculosis 0.037a 0.398 0.186a
No 1149 (98.8) 98.7 99.7 98.0 99.3 98.0 98.7 100.0 97.3 98.7
Yes 7 (0.6) 1.0 0.0 0.0 0.7 0.7 0.6 0.0 1.4 0.6
Does not know 7 (0.6) 0.3 0.3 2.0 0.0 1.4 0.7 0.0 1.4 0.6
History of non-sexual risk
Blood transfusion 0.059 <0.001 <0.001
No 1013 (85.8) 86.5 82.9 88.9 92.0 91.9 82.2 92.1 92.4 82.6
Yes 95 (8.1) 8.6 8.5 3.9 7.3 6.8 8.7 7.5 6.2 8.8
Does not know 72 (6.1) 4.8 8.5 7.2 0.7 1.4 9.1 0.5 1.4 8.6
Tattoos 0.012a 0.019a <0.001
No 965 (81.9) 83.7 81.5 73.9 83.6 77.7 82.3 86.9 72.4 82.4
Yes 198 (16.8) 15.2 17.8 22.2 16.4 22.3 15.8 13.1 27.6 15.7
Does not know 15 (1.3) 1.0 0.7 3.9 0.0 0.0 1.9 0.0 0.0 1.9
Piercing <0.001a <0.001 <0.001a
No 1086 (92.5) 94.1 87.7 95.4 86.4 92.5 94.9 87.7 86.9 94.8
Yes 70 (6.0) 5.0 10.3 0.7 12.1 7.5 3.3 9.9 13.1 3.5
Does not know 18 (1.5) 0.9 2.1 3.9 1.5 0.0 1.8 2.4 0.0 1.6
Note: Missing values range between 3 and 33.
ap-value for Fisher’s Exact Test.
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Conclusion
Among pregnant women knowledge of HIV trans-
mission modes was high but relevant misconceptions
were present, and knowledge regarding HBV and HCV
transmission modes was much lower. As a higher knowl-
edge level was found among women from high socioeco-
nomic positions, women’s empowerment is expected to
play a major role in a comprehensive strategy for
prevention.
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Abstract
The aim was to estimate the prevalence
of sexual and physical intimate partner vio-
lence (IPV) and its associated factors, in a
sample of pregnant women using antenatal
care (ANC) in Nampula province -
Mozambique. This cross-sectional study
was carried out in six health units in
Nampula, from February 2013 to January
2014. Overall, 869 participants answered
the Conflict Tactics Scale 2. The lifetime
and past year prevalence of sexual abuse
was 49% and 46%, and of physical abuse
was 46% and 44%, respectively. Lifetime
and past year sexual abuse was significantly
associated with living as a couple, alcohol
drinking and having a past diagnosis of
gonorrhea. Lifetime and past year physical
abuse increased significantly with age and
was associated with living as a couple, alco-
hol drinking and history with syphilis. The
prevalence of lifetime and previous year
violence among women using ANC was
high and similar showing that most women
were constantly exposed to IPV. ANC pro-
vides a window of opportunity for identify-
ing and acting on violence against women.
Introduction
Intimate partner violence (IPV) is a
major public health problem, with one in
every three women worldwide ever having
experienced sexual or physical IPV.1
Violence against women is a violation of
human rights, it limits the social participa-
tion of women, and results in a large range
of health consequences, particularly repro-
ductive health.2-5 Women sexually or phys-
ically abused by their partners often present
serious clinical conditions (e.g., mental dis-
orders, cardiovascular diseases and hyper-
tension) and societal adverse outcomes such
as physical and psychological trauma, limit-
ed sexual reproductive control and health
care seeking, illegal and unsafe
abortions.1,6,7 Women who have been sexu-
ally or physically abused by their partners
are twice likely to have an abortion, almost
twice likely to experience depression, and,
in some World Health Organization (WHO)
African regions1 an increased risk for unin-
tended pregnancy.8 Beyond the reported
consequences on women health, it can be
recognized that they are 16% more likely to
have a low-birth-weight baby and other
adverse pregnancy outcomes compared to
women who have not experienced partner
violence.1,6 Although studies on violence
against women from Africa are scarce,
available data from the WHO shows that the
Africa region presents a lifetime prevalence
of 36.6% of physical and/or sexual IPV
among ever-partnered women.1,4 In addi-
tion, there are African countries where the
prevalence against women is much higher,
such as South Africa,9 and Zimbabwe,10
with estimated prevalence of physical/sexu-
al partner violence of 55.5% and 42.8%,
respectively. In Mozambique, there is limit-
ed research on IPV against women, particu-
larly in northern part of the country where
the current study was carried out. However,
a previous study conducted in Maputo, the
capital of the country, found that 69.4% of
women reported one or more types of vio-
lence during the previous year.11 In a coun-
try with high gender inequities, it is expect-
ed a high prevalence of violence against
women and therefore is of paramount
important to implement strategies to moni-
tor the problem in these contexts, to intend
to reduce sexual and physical consequences
of violence against women.
In developed countries there is evidence
that screening IPV during pregnancy might
be of great contribution to plan interven-
tions in reproductive health services and
therefore to prevent and minimize the
impact of such violence.10,12 Antenatal care
can provide an important point of contact
where women can be screened for physical
and sexual violence and, for those who
report IPV, referred to services that can
assist them. This could serve as a supple-
mental screening tool to detect women who
have been victims of IPV, these could allow
to formulate public health intervention for
detection and prevention of violence.8,13 In
the African context, asking women about
violence during antenatal care may repre-
sent a unique opportunity to reach these
women and to assess the magnitude of this
issue though in such context we can expect
women to delay or omit antenatal care.
Thus, this study aimed to estimate the
prevalence of sexual and physical intimate
partner violence against women and its
associated factors, in a sample of women
using antenatal care in Nampula province,
in Mozambique.
Materials and Methods
Participants and setting
The participants were recruited in six
health units in Nampula Province,
Mozambique (Hospital Geral de Marrere,
Centro de Saúde 25 de Setembro, Centro de
Saúde 1º de Maio, Centro de Saúde de
Muhala Expansão, Centro de Saúde de
Namicopo and Centro de Saúde Hospital
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Psiquiátrico), from February 2013 to
January 2014. Pregnant women, who visit-
ed these primary health care facilities for
their first prenatal appointment, were eligi-
ble to participate in the study. 
Design/procedure
In each health facility, maternal and
child health nurses were trained to perform
the study procedures, namely to conduct the
interviews using a structured questionnaire.
After the training, a pilot study was con-
ducted to allow nurses to be familiarized
with the questionnaire as well as to harmo-
nize procedures. The sampling procedure
consisted in inviting to participate one in
every three women attending their first pre-
natal appointment. 1216 women gave their
informed consent among them 946 were or
have been in a relationship lasting more
than one month and were, therefore, eligible
to answer the Conflict Tactics Scale 2
(CTS2). 
Of the 946 women, 77 were excluded
from the analysis due to missing informa-
tion on violence measures. Therefore, 869
women were included in the final analysis,
among those, 40 women were not at the
moment of the interview in a relationship.
Measures
The questionnaire was administered by
trained nurses and information was collect-
ed on sociodemographic characteristics,
tobacco, alcohol and illegal drugs use, sex-
ual behavior (age at the first intercourse,
number of sexual partners in the last 6
months), gestational age at the first appoint-
ment, history of neonatal deaths, and also
diagnosis of sexually transmitted infections.
IPV was assessed using the conflict tac-
tics scales.14 Women were asked whether
they had been victims of various types of
IPV. The CTS2 covers psychological
aggression, physical assault, sexual coer-
cion, physical assault with injury. The acts
may have occurred once, twice, 3 to 5, 6 to
10, 11 to 20 or more than 20 times during
the previous year, had not occurred during
the previous year but before or never
occurred. 
Data analyses
For analysis, maternal age was catego-
rized in five categories ( >18, 18-20, 21-25,
26-29, ≥30 years), education was catego-
rized according to the Mozambique educa-
tion system (no education/did not finish pri-
mary school, primary school including the
first and second degree, secondary school,
and pre-university and university degree),
marital status was categorized in married or
in cohabitation vs. single or separated, and
occupation was classified in three cate-
gories: housewife or unemployed,
employed or farmer, and student.
Information was obtained on the age at
the first sexual intercourse and then cate-
gorised as ≤14, 15-19, >19 years, having
more than one sexual partner in the previ-
ous 6 months was recoded in yes or no.
Parity was classified as 0, 1, 2, 3, 4 or more,
the gestational age at the first appointment
was recoded in ≤14 weeks, 15-27 weeks,
≥28 weeks, roughly corresponding to
trimesters. For history of neonatal deaths
women were categorized as primigravidae,
multigravidae with no neonatal deaths and
multigravidae with neonatal deaths. Women
were also asked about previous diagnosis of
HIV, syphilis and gonorrhoea.
In this analysis we only used physical
assault acts (e.g., beat up), sexual coercion
acts (e.g., threaten to have sex) and injury
(e.g., bruises). For the present analysis we
considered that women had been abused
during the previous year, if they disclosed at
least one occurrence of abuse during that
period, independently of chronicity.
Statistical analysis
The data entrance was double checked.
The Chi-square test was used to compare
proportions. Significance level was set at
0.05. The odds ratio (OR) and respective
95% confidence intervals (95% CI) were
calculated through logistic regression, with
adjustment for the potential confounders.
The data analysis was performed using the
statistical software SPSS, version 22.
Ethical considerations
Participants were informed of study
procedures, benefits and risks of participa-
tion, and provided written informed consent
for interviews. All study procedures were
taken to ensure confidentiality and did not
change the health care provision routines.
The interviews were conducted in a consul-
tation office, where pregnant women fol-
lowed all the clinical recommended proce-
dures. Health care and support services
were offered for victims of either sexual or
physical violence.15 The study was
approved by Ministry of Health of
Mozambique and by National Bioethics
Committee of Mozambique.
Results
In this sample of 869 pregnant women
the lifetime prevalence of IPV sexual abuse
was 48.8% and that of physical abuse was
46.0%. During the previous year a similar
prevalence was found both for sexual abuse
(45.6%) and physical abuse (43.4%). The
sample characteristics are presented in
Table 1. Briefly, almost two thirds of
women were 25 years old or younger, 599
(68.9%) had primary school or less, 678
(78.0%) were housewives or unemployed
and 791 (91%) lived as a couple. As for
their sexual life, approximately half were 15
to 19 years old in their first sexual inter-
course and 735 (84.6%) had only one sexual
partner in the previous six months. In terms
of reproductive characteristics, 270 (31.1%)
were nulliparous and almost 20% (n=173)
had had four or more deliveries, 61 (7.0%)
had a neonatal death before. As for gesta-
tional age at the time of the first prenatal
appointment, 63 (7.2%) women were 14 or
less weeks, 455 (52.4%) were between 15
to 27 weeks and 334 (38.4%) were 28 or
more weeks. Drinking alcohol was reported
by 73 (8.4%) women. Previous diagnosis of
HIV was reported by 60 (6.9%) women, of
syphilis by 35 (4.0%) and of gonorrhoea by
21 (2.4%) women. Sexual and physical IPV
occurred in every age group. However,
physical violence tended to increase signif-
icantly with age after the age of 21-25
years, and this remained after adjusting for
education and living in couple (Table 2).
More educated women (secondary school
and pre-university and university degree)
were less likely to have experienced sexual
and physical IPV, both during lifetime and
in the previous year (Table 2). As well, stu-
dents were significantly less likely to report
both lifetime and past year sexual IPV, this
association was not statistically significant
for physical IPV. Women living as a couple
had approximately twice the odds of report-
ing sexual IPV both lifetime and past year.
This association was not statistically signif-
icant for physical IPV. History of alcohol
consumption was significantly associated
with reporting sexual and physical IPV at
any time period. There were no significant
differences in the prevalence of sexual
abuse and physical violence among women
who had one partner compared with those
who had more than one partner during the
previous six months. Women with their first
sexual intercourse after the age of 15 years
were significantly less likely to be physical-
ly abused both in lifetime and in the previ-
ous year, as well as those with their first
sexual intercourse after the age of 19 were
less likely to report lifetime physical abuse.
There was a crude association between mul-
tiparity with no deaths and with one or more
neonatal deaths and physical abuse, both in
lifetime and in the previous year (Table 1),
but this association lost significance after
adjustments (Table 2). No associations were
found for any other reproductive character-
istics. 
Pregnant women who reported a previ-
ous diagnosis of syphilis had twice the odds
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Table 1. Prevalence of sexual abuse, physical abuse and injury according to sociodemographics and behavioural characteristics, adverse
maternal outcomes and sexually transmitted infections; 2013/2014, Nampula, Mozambique.    
                                                                IPV Sexual abuse                            IPV Physical abuse and injury
                                                                            Lifetime           Past year                      Lifetime                   Past year
                                                           N=869          48.8%                           45.6%                        46.0%                         43.4%
                                                          N (%)*                      OR (95%CI)                 OR (95%CI)               OR (95%CI)              OR (95%CI)
Age, years                                                                                                                                                                                                                                                             
     <18                                                                148 (17.0)               44.6                   1                     43.9                  1                    34.5                  1                   33.8                 1
     18-20                                                              207 (23.8)               48.8      1.18 (0.77, 1.81)       45.4     1.06 (0.69, 1.62)       41.1     1.32 (0.85, 2.05)     37.7    1.18 (0.76, 1.84)
     21-25                                                              218 (25.1)               49.5      1.22 (0.80, 1.85)       46.8     1.12 (0.74, 1.71)       49.1     1.83 (1.19, 2.82)     46.3    1.69 (1.10, 2.61)
     26-29                                                              128 (14.7)               49.2      1.20 (0.75, 1.93)       46.9     1.13 (0.70, 1.81)       51.6     2.02 (1.25, 3.29)     46.9    1.73 (1.06, 2.81)
     ≥30                                                                154 (17.7)               51.3      1.31 (0.83, 2.06)       45.5     1.06 (0.68, 1.67)       55.2     2.34 (1.47, 3.73)     53.2    2.23 (1.40, 3.55)
Education                                                                                                                                                                                                                                                             
     No education/did not finish school       300 (34.5)               54.0                   1                     50.7                  1                    51.3                  1                   48.3                 1
     Primary school                                           299 (34.4)               48.5      0.80 (0.58, 1.11)       45.2     0.80 (0.58, 1.11)       47.5     0.86 (0.62, 1.18)     44.8    0.87 (0.63, 1.20)
     (1st and 2nd level completed)                                                       
     Secondary School                                      199 (22.9)               46.2      0.73 (0.51, 1.05)       43.2     0.74 (0.52, 1.06)       38.7     0.60 (0.42, 0.86)     35.7    0.59 (0.41, 0.86)
     Pre-University/University                           61 (7.0)                 29.5      0.36 (0.20, 0.65)       27.9     0.37 (0.21, 0.69)       36.1     0.53 (0.30, 0.94)     36.1    0.60 (0.34, 1.07)
Living as a couple                                                                                                                                                                                                                                               
     No                                                                    70 (8.1)                 31.4                   1                     28.6                  1                    34.3                  1                   32.9                 1
     Yes                                                                 791 (91.0)               50.1      2.19 (1.30, 3.69)       46.9     2.21 (1.29, 3.78)       47.0     1.70 (1.02, 2.84)     44.2    1.62 (0.97, 2.72)
Occupation                                                                                                                                                                                                                                                           
     Housewife/unemployed                           678 (78.0)               50.4                   1                     47.8                  1                    46.9                  1                   44.7                 1
     Employed/Farmer                                        75 (8.6)                 54.7      1.18 (0.73, 1.91)       44.0     0.86 (0.53, 1.39)       48.0     1.04 (0.65, 1.68)     40.0    0.82 (0.51, 1.34)
     Student                                                         110 (12.7)               33.6      0.50 (0.33, 0.76)       32.7     0.53 (0.35, 0.81)       39.1     0.73 (0.48, 1.10)     37.3    0.73 (0.49, 1.11)
Alcohol drinking                                                                                                                                                                                                                                                  
     No                                                                  787 (90.6)               47.5                   1                     44.3                  1                    44.1                  1                   41.4                 1
     Yes                                                                   73 (8.4)                 61.6      1.77 (1.09, 2.90)       57.5     1.70 (1.05, 2.76)       65.8     2.43 (1.47, 4.03)     63.0    2.41 (1.47, 3.96)
Age at first sexual intercourse, years                                                                                                                                                                                                     
     ≤14                                                                187 (21.5)               54.5                   1                     48.1                  1                    54.5                  1                   49.7                 1
     15-19                                                              444 (51.1)               48.2      0.77 (0.55, 1.09)       46.6     0.94 (0.67, 1.32)       44.1     0.66 (0.47, 0.93)     42.6    0.75 (0.53, 1.06)
     >19                                                                  32 (3.7)                 50.0      0.83 (0.39, 1.76)       43.8     0.84 (0.39, 1.78)       40.6     0.57 (0.27, 1.22)     40.6    0.69 (0.32, 1.48)
More than one sexual partner in the previous six months                                                                                                                                                                      
     No                                                                  735 (84.6)               47.8                   1                     44.9                  1                    44.2                  1                   41.9                 1
     Yes                                                                 118 (13.6)               50.0      1.09 (0.74, 1.61)       44.9     1.01 (0.68, 1.48)       53.4     1.44 (0.98, 2.13)     49.2    1.34 (0.91, 1.98)
Parity                                                                                                                                                                                                                                                                     
     0                                                                     270 (31.1)               47.4                   1                     45.2                  1                    37.4                  1                   35.2                 1
     1                                                                     154 (17.7)               42.2      0.81 (0.54, 1.21)       40.3     0.82 (0.55, 1.22)       40.9     1.16 (0.77, 1.74)     39.6    1.21 (0.80, 1.82)
     2                                                                     136 (15.7)               47.1      0.99 (0.65, 1.49)       45.6     1.02 (0.67, 1.54)       43.4     1.28 (0.84, 1.95)     41.2    1.29(0.84, 1.97)
     3                                                                     128 (14.7)               57.8      1.52 (1.00, 2.32)       53.9     1.42 (0.93, 2.16)       53.9     1.96 (1.28, 3.00)     53.2    2.02 (1.32, 3.10)
     ≥4                                                                  173 (19.9)               49.1      1.07 (0.73, 1.57)       42.8     0.91 (0.62, 1.33)       58.4     2.35 (1.59, 3.47)     52.6    2.04 (1.38, 3.02)
Gestational age at the first appointment, weeks                                                                                                                                                                                        
     ≤14                                                                  63 (7.2)                 42.9                   1                     42.9                  1                    36.5                  1                   36.5                  1
     15-27                                                              455 (52.4)               48.6      1.34 (0.79, 2.28)       45.3     1.19 (0.70, 2.02)       46.8     1.53 (0.89, 2.64)     44.0    1.36 (0.79, 2.35)
     ≥28                                                                334 (38.4)               49.1      1.29 (0.75, 2.23)       45.5     1.13 (0.66, 1.95)       46.1     1.49 (0.85, 2.59)     43.1    1.32 (0.75, 2.30)
Neonatal deaths                                                                                                                                                                                                                                                 
     Primigravidae                                              237 (27.3)               45.1                   1                     43.5                  1                    37.1                  1                   35.4                 1
     Multigravidae, no deaths                          558 (64.2)               48.6      1.15 (0.85, 1.57)       44.6     1.05 (0.77, 1.42)       47.1     1.51 (1.10, 2.06)     43.7    1.41 (1.03, 1.94)
     Multigravidade, ≥1 deaths                         61 (7.0)                 57.4      1.64 (0.93, 2.89)       55.7     1.64 (0.93, 2.89)       63.9     3.00 (1.67, 5.39)     63.9    3.23 (1.80, 5.80)
Previous HIV diagnosis                                                                                                                                                                                                                                     
     No                                                                  794 (91.4)               48.5                   1                     45.2                  1                    44.8                  1                   42.2                 1
     Yes                                                                   60 (6.9)                 53.3      1.21 (0.72, 2.05)       51.7     1.29 (0.77, 2.19)       60.0     1.85 (1.08, 3.15)     58.3    1.92 (1.13, 3.26)
     Do not know                                                   5 (0.6)                                                                                                                                                                                 
Previous syphilis diagnosis                                                                                                                                                                                                                              
     No                                                                 814 (93.7)               48.8                   1                     45.8                  1                    44.8                  1                   42.3                 1
     Yes                                                                  35 (4.0)                 51.4      1.11 (0.56, 2.19)       42.9     0.89 (0.45, 1.76)       62.9     2.08 (1.03, 4.19)     62.9    2.31 (1.15, 4.65)
     Do not know                                                   7 (0.8)                                                                                                                                                                                 
Previous gonorrhoea diagnosis                                                                                                                                                                                                                      
     No                                                                 823 (94.7)               48.0                   1                     48.8                  1                    45.2                  1                   42.6                 1
     Yes                                                                   21 (2.4)                 76.2      3.47 (1.26, 9.55)       71.4     3.08 (1.18, 8.01)       61.9     1.97 (0.81, 4.80)     61.9    2.18 (0.90, 5.33)
     Do not know                                                 19 (2.2)                                                                                                                                                                                
*Proportions in this column do not add up to 100 due to missing values. IPV, intimate partner violence; OR, odds ratio; CI, confidence interval; HIV, human immunodeficiency virus.                                         
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of reporting physical violence in their life-
time (aOR=2.07; 95% IC: 0.99-4.34), and
in the previous year (aOR=2.30; 95% IC:
1.10-4.81). Similar findings were found for
previous gonorrhoea diagnosis and sexual
abuse in lifetime and in the previous year.
Although there was a crude significant
association with previous HIV diagnosis
and sexual abuse, it lost significance after
adjusting for age, education and living in
couple.
Table 2. Association (Adjusted OR (95% CI) between sexual abuse, physical abuse and injury, sociodemographics and behavioural char-
acteristics, adverse maternal outcomes and sexually transmitted infections; 2013/2014, Nampula, Mozambique.
                                                                                               IPV Sexual abuse                                          IPV Physical abuse and injury
                                                                                           Adjusted OR (95%CI)*                                      Adjusted OR (95%CI)°  
                                                                                   Lifetime                         Past year                      Lifetime                         Past year
Age, years                                                                                                                                                                                                                                                         
      <18                                                                                                      1                                                 1                                              1                                                  1
      18-20                                                                                       1.19 (0.77, 1.83)                       1.06 (0.69, 1.63)                   1.36 (0.87, 2.12)                       1.21 (0.77, 1.89)
      21-25                                                                                       1.30 (0.85, 2.00)                       1.18 (0.77, 1.82)                   1.93 (1.24, 3.00)                       1.76 (1.13, 2.73)
      26-29                                                                                       1.11 (0.69, 1.81)                       1.03 (0.63, 1.68)                   2.00 (1.22, 3.28)                       1.70 (1.04, 2.80)
      ≥30                                                                                         1.28 (0.80, 2.05)                       1.02 (0.64, 1.63)                   2.29 (1.42, 3.69)                       2.16 (1.34, 3.49)
Education
      No education/did not finish school                                              1                                                 1                                              1                                                  1
      Primary school (1st and 2nd degree)                              0.81 (0.58, 1.11)                       0.81 (0.58, 1.11)                   0.96 (0.69, 1.34)                       0.97 (0.69, 1.35)
      Secondary School                                                               0.74 (0.51, 1.06)                       0.74 (0.52, 1.07)                   0.67 (0.46, 0.98)                       0.66 (0.45, 0.97)
      Pre-University/University                                                  0.38 (0.21, 0.69)                       0.40 (0.22, 0.74)                   0.53 (0.30, 0.96)                       0.60 (0.33, 1.08)
Living as a couple                                                                                                                                                                                                                                           
      No                                                                                                        1                                                1                                              1                                                  1
      Yes                                                                                          2.10 (1.23, 3.60)                       2.14 (1.23, 3.72)                   1.59 (0.93, 2.71)                       1.53 (0.89, 2.63)
Occupation
      Housewife/unemployed                                                                  1                                                 1                                              1                                                  1
      Employed/Agriculture/Farmer                                         1.28 (0.77, 2.13)                       0.88 (0.53, 1.46)                   0.94 (0.56, 1.57)                       0.69 (0.41, 1.18)
      Student                                                                                  0.58 (0.37, 0.92)                       0.62 (0.39, 0.99)                   1.25 (0.78, 1.99)                       1.24 (0.77, 1.99)
Alcohol drinking
      No                                                                                                        1                                                 1                                              1                                                  1
      Yes                                                                                          2.11 (1.25, 3.56)                       1.98 (1.18, 3.33)                   2.44 (1.42, 4.20)                       2.42 (1.41, 4.09)
Age at first sexual intercourse, years 
      ≤14                                                                                                       1                                                 1                                              1                                                  1
      15-19                                                                                       0.85 (0.59, 1.21)                       1.04 (0.74, 1.49)                   0.57 (0.39, 0.83)                       0.68 (0.46, 0.99)
      >19                                                                                         1.02 (0.47, 2.20)                       1.02 (0.47, 2.22)                   0.41 (0.18, 0.93)                       0.52 (0.23, 1.17)
More than one sexual partner in the last six months                                                                                                                                                                           
      No                                                                                                        1                                                 1                                              1                                                  1
      Yes                                                                                          1.06 (0.71, 1.58)                       0.96 (0.64, 1.44)                   1.34 (0.90, 2.01)                       1.25 (0.83, 1.87)
Parity                                                                                                           
      0                                                                                                            1                                                 1                                              1                                                  1
      1                                                                                              0.78 (0.52, 1.18)                       0.79 (0.52, 1.19)                   0.93 (0.59, 1.46)                       1.02 (0.65, 1.60)
      2                                                                                              0.99 (0.65, 1.50)                       1.02 (0.67, 1.55)                   0.91 (0.55, 1.50)                       0.94 (0.57, 1.57)
      3                                                                                              1.42 (0.92, 2.20)                       1.32 (0.85, 2.04)                   1.32 (0.77, 2.26)                       1.40 (0.82, 2.41)
      ≥4                                                                                           0.92 (0.62, 1.37)                       0.77 (0.51, 1.15)                   1.43 (0.80, 2.55)                       1.18 (0.66, 2.11)
Gestational age at the first appointment, weeks                                                                                                                                                                                    
      ≤ 14                                                                                                     1                                                 1                                              1                                                  1
      15-27                                                                                       1.16 (0.67, 2.01)                       1.02 (0.59, 1.76)                   1.42 (0.81, 2.50)                       1.27 (0.72, 2.22)
      ≥28                                                                                         1.20 (0.68, 2.10)                       1.04 (0.59, 1.82)                   1.25 (0.70, 2.23)                       1.11 (0.62, 1.98)
Neonatal deaths 
      Primigravidae                                                                                    1                                                 1                                              1                                                  1
      Multigravidae, no deaths                                                   1.12 (0.82, 1.53)                       1.02 (0.75, 1.40)                   0.97 (0.64, 1.46)                       0.96 (0.63, 1.45)
      Multigravidade, ≥1 deaths                                                1.50 (0.83, 2.70)                       1.50 (0.83, 3.80)                   1.69 (0.86, 3.33)                       1.91 (0.97, 3.76)
Previous HIV diagnosis                                                                                                                                                                                                                                  
      No                                                                                                        1                                                 1                                              1                                                  1
      Yes                                                                                          1.09 (0.63, 1.88)                       1.25 (0.72, 2.16)                   1.47 (0.83, 2.58)                       1.54 (0.88, 2.71)
Previous syphilis diagnosis                                                                                                                                                                                                                          
      No                                                                                                        1                                                 1                                              1                                                  1
      Yes                                                                                         1.18 (0.59, 2.36)                       0.93 (0.46, 1.86)                   2.07 (0.99, 4.34)                       2.30 (1.10, 4.81)
Previous gonorrhoea diagnosis                                                                                                                                                                                                                   
      No                                                                                                        1                                                 1                                              1                                                  1
      Yes                                                                                          3.32 (1.15, 9.64)                       2.88 (1.04, 7.93)                   1.54 (0.59, 4.01)                       1.70 (0.65, 4.41)
*Adjusted for education and living in couple; °Adjusted for age, education and living in couple. IPV, intimate partner violence; OR, odds ratio; CI, confidence interval; HIV, human immunodeficiency virus.
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Discussion
The lifetime prevalence of sexual and
physical IPV was high, with 48.8% of preg-
nant women experiencing sexual violence
and 46.0% physical abuse during their life-
time. A similar prevalence was found both
for sexual abuse (45.6%) and physical
abuse (43.4%) during the previous year,
indicating that abuse is a continuum in life.
These high prevalence are consistent with
studies conducted worldwide,16 and in
Africa showing an overall prevalence of
20%-70%.1,4,17 Similar results were found
in the neighbouring Zimbabwe where the
prevalence was estimated at 46.2% for
physical and/or sexual violence.10 The high
prevalence observed in this study of IPV
could be related to the patriarchal ideology
in traditional societies such as found in
Mozambique, where gender roles are dis-
torted to justify violence against women,
who are mostly assigned an inferior role to
men.18,19 In addition, the low level of edu-
cation, young age and low socio-economic
status and HIV diagnosis could contribute
for higher prevalence of IPV.4 On the other
hand, more educated women were shown to
report less violence, supporting that increas-
ing women’s education empowers them.
Physical abuse increased with age,
being approximately twice as likely in
women aged 21 years and over, even after
adjusting for education and living with a
partner. These results are similar to those of
a study in Rwanda, which shows that
women aged 26 -34 were more likely to suf-
fer physical abuse,20 suggesting that males
may use violence between partners to con-
trol sexual decision making and coercive
sex.21
Initiating sexual intercourse at age 15
and older seems to be a protective factor,
with an inverse relationship between age at
the onset of sexual intercourse and the pos-
sibility of physical violence, and this trend
was maintained when adjusted for educa-
tion and living with the partner. This finding
is consistent with other studies which show
the importance of a delay in the onset of
sexual intercourse as a protective factor,22-24
on other hand the young age has been con-
sidered as a most factor associated with
increased likelihood of IPV.25
A significant association was found
between exposure to sexual violence and
diagnosis of gonorrhoea and also between
physical violence and syphilis diagnosis. It
is known that IPV is concurrent with a high-
er risk of sexually transmitted diseases
(STD), as well as a reduction in women’s
use of contraception,26,27 due to violent
behaviour by male partner.28 However, this
result must be read carefully as a small
number of women reported a previous diag-
nosis of these STD.
Multigravidae with one or more still-
births were at a 3-fold increased risk for
physical abuse compared to primigravidae,
although after adjustment the strength of the
association decreased. These findings seem
to show that exposure to physical violence
has an impact in pregnancy outcomes. In
this study we were not able to determine if
reported violence has occurred during preg-
nancy, however, there is strong evidence
from African studies that a history of expe-
riencing abuse in lifetime and in the previ-
ous 12 months is significantly associated
with IPV in pregnancy or just before preg-
nancy.4,29,30
Strengths and limitations
The Conflict Tactics Scales has been
used frequently in many studies since 1972.
The CTS is a measurement tool for research
program of the family conflicts, it was
revised by Murray Straus et al, in 1979. The
theoretical basis of the CTS is conflict the-
ory, assuming that conflict is an inevitable
part of all human. The CTS2 replaces the
matrix format developed for research with
military families,14 and the instrument has
been adapted to be applied on researches in
Mozambique context.11
Although the questionnaires were
administered to pregnant women using
antenatal care, violence during pregnancy
was not assessed. However, a high propor-
tion of women reported sexual and physical
abuse during the previous year, and there-
fore, we may speculate that pregnancy
could not stop the violence episodes. Also,
we sampled a specific group of women that
seek for the antenatal care. It is known that
in such contexts, women tend to avoid ante-
natal care and sometimes deliver at home.
Due to its cross-sectional nature, the study
cannot provide causal links and there is
possible information/disclosure bias. Thus,
we might expect a high prevalence of vio-
lence in the general population and also an
underestimation of the associations found. 
Conclusions
This study found a high prevalence of
lifetime and past year violence among
women using antenatal care in
Mozambique. Antenatal care provides a
window of opportunity for identifying and
acting on violence against women.
Therefore, it is necessary to define specific
strategies to support women in the context
of Mozambique. 
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6. DISCUSSION 
 
In this study, we found a high lifetime sexual and physical prevalence IPV with 48.8% 
of pregnant women experiencing sexual violence and 46% physical. A similar prevalence was 
found for sexual, 46% and physical abuse 44% during the past year, indicating that abuse is 
common and is a continuum in life (127).  A study conducted in Egypt reported a prevalence 
of 44.1% of pregnant women studied. Among women who reported violence, 32.6% were 
sexual and 15.9% physical violence (128). The Africans studies have shown, a high prevalence 
of IPV against pregnant women, an overall prevalence of 20% - 70% (59, 129).  
 
In this study education showed to play a protection role, more educated women (pre-
university and university), were less likely to have experienced sexual abuse and physical 
violence, during lifetime and in past year. Similar findings were reported with other studies, 
which besides the level of education, the low-income household were also higher vulnerable 
to violence perpetrated for their partners (61, 130).  
 
Women with their first sexual intercourse after the age of 15 years were less likely to 
be sexually or physically abused, compared with those who had their sexual experience before 
being 14 years old. This finding aligns with other studies that emphasize the importance of 
delay the onset of sexual intercourse as a protective factor (131, 132). 
 
The latent class analysis for Knowledge regarding modes of transmission HIV, HBV, 
and HCV, showed a high knowledge for HIV, with 60.5% of pregnant women represented in 
class 1, where we observed the highest proportion of correct answers and the probability of 
correct answers than false items. For HBV and HCV in the corresponding criteria for class 1, 
the percentages were 23.6% and 18.4%, respectively. The knowledge regarding HIV modes 
of transmission is high compared with the hepatitis virus, which is consistent with the rates 
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found in pregnant women in other African countries (133, 134). These finding, in the country, 
could be explained by the massive campaign and structured programs of health education 
related to HIV prevention measures in schools, at health facilities and in communities across 
the country (135-137) most of the health educations programs were implemented within the 
framework of the response to the national strategic plans (138) may have contributed to 
increase the awareness of HIV modes of transmission and prevention measures.   
 
The knowledge of the modes of transmission of HBV is lower compared with HIV 
knowledge, which was already evident in the lower frequency of respondents that had ever 
heard about HBV. This is particularly concerning since HBV, is endemic in the country (35, 
98). The inadequate knowledge on HBV transmission modes was also reported in other 
countries showing the need for interventions that may increase awareness and knowledge on 
hepatitis B, its modes of transmission, impact on health by community education programs, 
supplemented by the safe and effective vaccine for women at high risk (139, 140). The 
immunization of children against HBV could provide an opportunity to intervene by building a 
consistent awareness program intended to increase the knowledge about HBV infection (86, 
141). 
 
Knowledge about modes of HCV transmission is the lowest which can be partially 
explained by the low prevalence of HCV infection in the country (35, 98), however their 
evidence that vertical transmission of HCV is a major risk for chronic carries (142).  
Nevertheless, the fact that the prevalence of anti-HCV is increasing, early awareness 
programs could warning to start monitoring HCV infection closely, since, among other risk 
factors, the co-infections with HIV, increase the possibility of HCV vertical transmission up to 
19.4% (143) which may cause, in the future, a major concern in public health (97) A global 
response is required by renewing the primary prevention, vaccine development to prevent 
vertical transmission (97, 144) this fact brings a challenge to the health authorities to design 
health policies that include HCV programs as part of awareness campaign aimed at increasing 
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knowledge of modes of HCV transmission among specific group risk, including women and the 
general population. 
 
There are few studies conducted and published in Mozambique reporting the co-
infection of HIV, HBV, and HCV. One published study was conducted among replacement 
blood donors, in Maputo Central Hospital (35).  In HIV positive donors they found that 8.6% 
were suffering from a chronic infection with HBV, 2.1% were HBeAg+ and 1.3% had anti-HCV. 
This data is consistent with other studies conducted in African countries such as Cameroon 
where was reported a prevalence of 23.7% in people infected with HIV were HBsAg+, amongst 
those  patients 12% also tested positive for HBeAg, which indicates that viral replication was 
active, and 7.2% were Anti-HCV+, and the co-infected prevalence for both HBV and HCV was 
2% (87). 
 
In this study, 30 (9.8%) of HIV individuals were positive for HBsAg, and 5 (1.8%) had a 
chronic infection. It is known that the high frequency of chronic HBV infection in HIV-infected 
people, is linked to serious consequences in resource-limited settings, related to the significant 
increase in morbidity and mortality from liver problems (145, 146) and the negative impact 
related to the pathophysiology of HIV infection (147), increasing therefore the risk of death in 
these patients compared to those who are infected with HIV (148, 149).  
 
The prevalence of HBV is higher in Mozambique, for instance, a study on blood donors 
conducted in Maputo Central Hospital, Maputo City found a global prevalence estimated at 
9.3% for HBsAg among blood donors, (35). In another study, conducted in Tete province, found 
a prevalence of 10.6%, where 90% of participants were men (38). Due to the shared mode of 
transmission of both viruses (HBV and HIV) co-infection is also common in people infected 
with HIV in African countries (91), with the advent of ART, the liver disease has been the cause 
of mortality for people infected with HIV and HBV compared to monoinfected patients with HIV 
(150). In this study, we found a prevalence of 9.8% in coinfected individuals (HIV + and HBsAg 
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+) and HBeAg was present in 2.1% HIV-HBV coinfected people. This data is consistent with 
studies in African countries where co-infection with HBV is present in HIV-infected people 
varies from 0% to >28.4% (146). Other studies recommend that in African countries, where 
the base of ART is the Nevirapine, the elevation of transaminases ALT, in HIV positive 
individuals at baseline or during treatment, should be a sufficient argument for testing the 
coinfections, mainly for HBV (151).  
The HCV coinfection in HIV-infected people is poorly documented in Mozambique, a 
study conducted, in Maputo, among men and women blood donors found a prevalence of 1.2 
and 1.0% of Anti-HCV, respectively (35). In this study, we found a co-infection of 1 (0.2%). 
Although it is known that HIV+ people, the chance of HCV infection is higher, but evidence 
from African studies indicate a prevalence of 0.76% for HIV/HCV (91), from the systematic 
review study conducted in Africa Sub-Saharan, showed a greater predominance of HIV/HBV 
coinfection compared to HIV/HCV coinfection (92). 
 
The study did not found the simultaneous co-infection by the three viruses. In a study 
conducted in Abuja, Nigeria, showed a prevalence of 0.7% in HIV-infected people, with HBV 
and HCV (88). These findings can be explained by the wide variation in the way of transmission 
of these viruses, depending on regions such as Europe, Asia, Central and South America, 
where most transmissions occur through injectable drug use (89), this study also found 1.3% 
of Anti-HCV seroprevalence in HIV-infected individuals.  Therefore, this prevalence should be 
compared to studies conducted in other countries in sub-Saharan Africa where was found a 
similar prevalence of 1.2% of Anti-HCV positive (90). 
 
With regard to co-infection with HIV/HBV in pregnant women, it does not increase the 
risk of HIV transmission (115), however it is crucial to study the coinfection among pregnant 
women, because these women are a significant reservoir for horizontal or perinatal 
transmission of HBV and the establishment of routine screening to such women could allow 
an identification of new baby born that require an active or passive immunoprophylaxis at birth, 
79 
 
which may reduce the risk of HBV perinatal transmission in coinfected women that are 
considered to be of high risk (100, 152). A history of induced abortion, baseline ALT elevated 
are significantly associated with HBV infection (113).  
 
In Africa, 40% to 60% of people who are chronic carriers of HBV, have been transmitted 
during pregnancy (116). The WHO recommends that in countries where the prevalence of HBV 
is higher, pregnant women must be screened for this virus in order to start the treatment 
recommended in the first quarter of pregnancy (117). In that, the study found HIV/HBsAg+ co-
infection with HIV and HBV of 24 (3.6%) in pregnant women. These results are consistent with 
studies in other African countries, which found HIV/HBV co-infection prevalence of 3.1%, in 
Kwazulu Natal (100), and 2.3% in Luanda, Angola (9). 
 
This study found HIV/HCV coinfection of 1 (0.2%). Similar studies results, in Tanzania 
and Angola, showed that MTCT does not play a significant role in HCV transmission (9, 106). 
The co-infection HIV/HCV, although is not a public health problem in Mozambique, it is known 
that factors such as the Maternal HIV coinfection, HCV maternal viral load, intrapartum invasive 
procedures play a great roll on HCV maternal transmission (122, 123). A study conducted in 
Burkina Faso, the prevalence of HIV/HCV co-infection was 2.38% (124), these results are 
aligned with the observed in the present study. 
 
Finally, in Sub-Saharan Africa, where is the heart of HIV pandemic, there is a 
preponderance of HIV and HBV co-infection compared to HIV and HCV, leading to a significant 
limitation of HCV seroprevalence surveys published, in the region  (92). Although screening 
and treatment for syphilis is part of routine health services, in Sub-Saharan African countries 
(153-155), there are factors associated with failure of screening during antenatal care such as 
attending antenatal care in private health facility, previous adverse outcome, not being 
screened for HIV. The odds of being unscreened increase with decreasing education level (P 
=0.02) and with decreasing doses of intermittent preventive treatment received for malaria 
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during pregnancy (P< 0.001), some of the women´s personal characteristics and type of health 
facility where was received (154). AIDS mortality may have played an important role in the 
decline of bacterial sexually transmitted infections such as syphilis, but the relatively scale-up 
of antiretroviral therapy may result in a resurgence of syphilis and other sexually transmitted 
infections as observed in high-income countries (156).  
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7. CONCLUSION 
 
The prevalence of intimate partner violence is very high among women in this study. 
Contact with women in prenatal care provides is a window of opportunity for identifying women 
who experience violence to undergo screening for sexually transmitted infections. Latent class 
models (LCM) showed a high knowledge of HIV modes of transmission, but that of HBV and 
HCV was little known. In this setting, the prevalence of HIV and hepatitis B among pregnant 
women was very high, syphilis being unexpectedly low. HBV may also have been transmitted 
horizontally in children, and screening for HBsAg could contribute substantially to avert the 
negative impact on morbidity and mortality of HIV/HBV coinfected individuals, reinforcing the 
central role of prenatal care. 
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8. OUTCOMES 
 
1) This work could contribute to reducing morbidity and mortality among pregnant women and 
their offspring infected by HIV, HBV, and HCV.  It will give a scientific contribution to the 
country of Mozambique for the possible introduction of protocols for testing HBV and HCV, 
thereby creating the appropriate protocols for treating these co-morbidities in pregnant 
women at antenatal care. 
 
2) Contribute to raising other research projects in the area of infectious diseases in the 
country, mainly on HBV and HCV. 
 
3) Contribute to the promotion of scientific and /or academic meetings.
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